Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.4.2.4 - thymidine phosphorylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in endometrial cancer.
Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer.
Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.
Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases.
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Different angiogenic pathways in human cervical cancers.
Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines.
Effects of sex steroids and growth factors on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in ovarian adenocarcinoma OMC-3 cells.
Expression of platelet-derived endothelial cell growth factor in prostatic adenocarcinoma.
Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas.
Gene Regulation and Clinical Roles for Interferons in Neoplastic Diseases.
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo.
Papers to appear in forthcoming issues
Platelet-derived endothelial cell growth factor as a prognostic factor for radiotherapy outcome in patients with adenocarcinoma of the uterine cervix.
Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Prognostic role of angiogenesis and its correlations with thymidine phosphorylase and p53 expression in ductal adenocarcinoma of the pancreas.
STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging.
The expression of thymidine phosphorylase and its correlation with angiogenesis in gastric adenocarcinoma.
The influence of 5-fluorouracil on activity of thymidine phosphorylase in gastric adenocarcinoma and normal adjacent tissue.
The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget's disease of the vulva and breast.
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Thymidine phosphorylase expression in gallbladder adenocarcinomas.
Thymidine phosphorylase expression is predominantly observed in stroma of well-differentiated adenocarcinoma of endometrium and correlates with a frequency of vascular involvement.
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
[Lactate dehydrogenase, adenosine deaminase and thymidine phosphorylase activity of blood and tissues in breast tumor patients]
Adenocarcinoma of Lung
Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma.
Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma.
Adenocarcinoma, Papillary
Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum.
Adenocarcinoma, Scirrhous
[The alteration of PyNPase activity in breast cancers due to preoperative oral administration of 5'-DFUR]
Adenofibroma
[Lactate dehydrogenase, adenosine deaminase and thymidine phosphorylase activity of blood and tissues in breast tumor patients]
Adenoma
Concurrent expression of angiogenic growth factors and neovascularization during tumourigenesis in colorectal carcinoma patients.
Differential expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) in nonpolypoid and polypoid lesions of the colon.
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions.
Neoplastic stroma and epithelium show up-regulation of platelet-derived endothelial cell growth factor/thymidine phosphorylase in colorectal carcinomas but not adenomas.
The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion.
The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas.
Thymidine phosphorylase expression in human colorectal mucosa, adenoma and carcinoma: role of p53 expression.
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
Variations in the expression of platelet-derived endothelial cell growth factor in human colorectal polyps.
[Determination of thymidine phosphorylase in adenoma and cancer of the human prostate]
Ameloblastoma
Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors.
Angiofibroma
Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis.
Arthritis
The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis.
Arthritis, Rheumatoid
2-Arylquinazolin-4(3H)-ones: A novel class of thymidine phosphorylase inhibitors.
Expression of the angiogenic factor thymidine phosphorylase in THP-1 monocytes: induction by autocrine tumor necrosis factor-alpha and inhibition by aspirin.
Serum gliostatin levels in patients with rheumatoid factor-negative and -positive rheumatoid arthritis and changes of these levels after surgical treatments.
Synthesis, molecular docking study and thymidine phosphorylase inhibitory activity of 3-formylcoumarin derivatives.
The Janus kinase inhibitor tofacitinib inhibits TNF-?-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes.
Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3.
Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synoviocytes.
Astrocytoma
Neurotrophic action of gliostatin on cortical neurons. Identity of gliostatin and platelet-derived endothelial cell growth factor.
Stromal angiogenesis in human glioma: a role of platelet-derived endothelial cell growth factor.
Ataxia Telangiectasia
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
Atherosclerosis
Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis.
Highly accumulated platelet vascular endothelial growth factor in coagulant thrombotic region.
Thymidine phosphorylase participates in platelet signaling and promotes thrombosis.
Bile Duct Neoplasms
Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.
Biliary Tract Neoplasms
Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.
Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy.
Bone Diseases
Pinpointing a Factor in Myeloma Bone Disease.
Bone Resorption
Pinpointing a Factor in Myeloma Bone Disease.
Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma.
Brain Diseases
Anesthetic Considerations for Liver Transplantation in a Patient with Mitochondrial Neurogastrointestinal Encephalopathy Syndrome.
Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B.
MNGIE Syndrome: Liver Cirrhosis Should Be Ruled Out Prior to Bone Marrow Transplantation.
Non-myeloablative bone marrow transplant and platelet infusion can transiently improve the clinical outcome of mitochondrial neurogastrointestinal encephalopathy: A case report.
Novel sequence variations in the thymidine phosphorylase gene causing mitochondrial neurogastrointestinal encephalopathy.
Primary muscle diseases in Thammasat University Hospital: muscle biopsy study of 12 cases.
Brain Neoplasms
In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors.
Intracavitary chemotherapy with 5-fluoro-2'-deoxyuridine (FdUrd) in malignant brain tumors.
Intrathecal 5-fluoro-2'-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study.
Stromal angiogenesis in human glioma: a role of platelet-derived endothelial cell growth factor.
Transduction of thymidine phosphorylase cDNA facilitates efficacy of cytosine deaminase/5-FC gene therapy for malignant brain tumor.
[5'-Deoxy-5-fluorouridine and 5-fluorouracil concentrations and thymidine phosphorylase activity in brain tumors following intravenous administration of 5'-deoxy-5-fluorouridine]
[Activities of pyrimidine nucleoside phosphorylase in brain tumors and antitumor effect of 5'-DFUR]
[Pyrimidine nucleoside phosphorylase in brain tumors and anti-tumor effect of 5'-DFUR]
Breast Diseases
[Prognostic effect of PyNPase (pyrimidine nucleoside phosphorylase) activity in breast cancer]
Breast Neoplasms
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling.
Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells.
Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma.
Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting.
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Clinical significance of determination of surrogate markers of angiogenesis in breast cancer.
Clinical usefulness of oral combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR) and cyclophosphamide for metastatic breast cancer.
Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications.
Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Comparison of ELISA level and immunohistochemical status for thymidine phosphorylase (TP) in invasive breast carcinoma.
Correlation between elevated intratumoral thymidine phosphorylase and prognosis of node-positive breast carcinoma undergoing adjuvant doxifluridine treatment.
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Effects of introduction of dThdPase cDNA on sensitivity to 5'-deoxy-5-fluorouridine and tumor angiogenesis.
Effects of orally administered 5-fluorouracil and its derivative 5'-deoxy-5-fluorouridine on 7,12-dimethylbenz[a]anthracene-induced breast carcinomas in rats.
Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients.
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer.
Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in human breast carcinoma cells and tissues.
Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel.
Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: implication for method to detect expression of these molecules in clinic.
Expression of uridine and thymidine phosphorylase genes in human breast carcinoma.
HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer.
Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines.
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer.
Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
Localization of thymidine phosphorylase in breast cancer tissue.
Mitomycin C and capecitabine combination (MiXe) in heavily pretreated metastatic breast cancer patients. A dose-finding study.
Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer.
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
Papers to Appear in Forthcoming Issues
Papers to appear in forthcoming issues
Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer.
Prediction of the effect of 5'-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients.
Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients.
Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data.
Prognostic value of thymidine phosphorylase expression in breast carcinoma.
Pyrimidine nucleoside phosphorylase-activity and biological characteristics of breast-cancer.
Regulation of endothelial growth factor expressions in breast cancer.
Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer.
Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF.
Reproducible immunohistochemical criteria based on multiple raters' judgments for expression of thymidine phosphorylase in breast cancer tissue.
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.
Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer.
Synthesis, thymidine phosphorylase inhibitory and computational study of novel 1,3,4-oxadiazole-2-thione derivatives as potential anticancer agents.
The activity of thymidine phosphorylase correlates with tumor size and lymph nodes status in breast carcinoma.
The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium.
The influence of elevated levels of platelet-derived endothelial cell growth factor/thymidine phosphorylase on tumourigenicity, tumour growth, and oxygenation.
The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo.
The influence of pyrimidine nucleoside phosphorylase activity on metastasis of breast cancer.
The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas.
Thymidine phoshorylase expression in breast cancer: the prognostic significance and its association with other angiogenesis related proteins and extracellular matrix components.
Thymidine phosphorylase and breast carcinoma.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results.
Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.
Thymidine Phosphorylase Expression and Microvascular Density Correlation Analysis in Canine Mammary Tumor: Possible Prognostic Factor in Breast Cancer.
Thymidine phosphorylase expression correlates with tumor differentiation and Bcl-2 in invasive breast cancer.
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Thymidine phosphorylase is regulated by tamoxifen in T47D breast cancer cell line.
Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.
Up-regulated pyrimidine nucleoside phosphorylase in breast carcinoma correlates with lymph node metastasis.
Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast.
Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer.
[Activity of the enzymes of DNA metabolism in the blood of patients with breast cancer]
[Clinical significance of pyrimidine nucleoside phosphorylase (PyNPase) in breast cancer]
[Demonstration of pyrimidine nucleoside phosphorylases in breast cancer]
[Distributions of pyrimidine nucleoside phosphorylase (PyNPase) in tissues of benign and malignant mammary diseases--immunohistochemical observations]
[Estimation of level of enzyme induction of thymidine phosphorylase, dihydropyrimidine dehydrogenase, and thymidylate synthase in primary and recurrent breast cancer]
[Expressions of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase in breast cancer and their correlations with prognosis.]
[Influences of 5'-deoxy-5-fluorouridine (5'-DFUR) on cell cycle in patients with breast cancer]
[Lactate dehydrogenase, adenosine deaminase and thymidine phosphorylase activity of blood and tissues in breast tumor patients]
[Measurement of PyNPase and analysis on correlation between breast cancer tissue and lymph node]
[Prognostic effect of PyNPase (pyrimidine nucleoside phosphorylase) activity in breast cancer]
[PyNPase and DPD expression potentially predict response to 5'-DFUR treatment for node-positive breast cancer patients]
[Relationships among the expression of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase and the prognosis of breast cancer]
[Significance of pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase levels to predict postoperative recurrence in primary breast cancer]
[Significance of tissue PyNPase, TS, and DPD activities in breast cancer]
[The correlation between thymidine phosphorylase levels detected by new assay methods (ELISA) and enzyme activity assay (HPLC) in breast cancer]
[The study of 5-FU levels and pyrimidine nucleoside phosphorylase (PyNPase) activity in human breast cancer tissue after administration of 5'-deoxy-5-fluorouridine (5'-DFUR)]
[Use of enzyme test in chemotherapy of patients with cancer of the breast]
Carcinogenesis
Anti-tumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis.
Expression of granulocyte colony-stimulating factor receptor and platelet-derived endothelial cell growth factor in oral and oropharyngeal precancerous lesions.
Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor.
Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors.
Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma.
Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue.
Variations in the expression of platelet-derived endothelial cell growth factor in human colorectal polyps.
Carcinoma
5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression.
A case report of papilla Vater carcinoma showing positive expression of thymidine phosphorylase.
Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma.
Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast.
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer.
Angiogenesis in ovarian clear cell carcinoma and its relation to endometriosis.
Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival.
Angiogenic growth factors in preinvasive breast disease.
Angiogenic switch occurs during the precancerous stage of human esophageal squamous cell carcinoma.
Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase.
Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts.
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Clinical value of thymidine kinase in patients with cervical carcinoma.
Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma.
Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma.
Coexpression of cyclooxygenase-2 and thymidine phosphorylase as a prognostic indicator in patients with FIGO stage IIB squamous cell carcinoma of uterine cervix treated with radiotherapy and concurrent chemotherapy.
Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma.
Comparative antitumor activity and intestinal toxicity of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine.
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Concurrent expression of angiogenic growth factors and neovascularization during tumourigenesis in colorectal carcinoma patients.
Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.
Correlation between expression levels of thymidine phosphorylase (dThdPase) and clinical features in human gastric carcinoma.
Correlation between expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) and microvessel density in early-stage human colon carcinomas.
Correlation between thymidine phosphorylase expression and invasion phenotype in cervical carcinoma cells.
Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma.
Correlation between tumor angiogenesis and expression of thymidine phosphorylase, and patient outcome in uterine cervical carcinoma.
Differences and relationships of thymidine phosphorylase expression in tumor-associated macrophages and cancer cells in squamous cell carcinoma of the esophagus.
Different angiogenic pathways in human cervical cancers.
Differential expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) in nonpolypoid and polypoid lesions of the colon.
Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines.
Distribution of thymidine phosphorylase activity in gastric carcinoma and adjacent normal gastric tissue.
Effect of intratumoral OK-432 administration of thymidine phosphorylase expression in human gastric carcinoma.
Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Effects of smoking and alcohol consumption on 5-fluorouracil-related metabolic enzymes in oral squamous cell carcinoma.
Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.
Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma.
Expression of basic fibroblast growth factor is associated with a good outcome in patients with squamous cell carcinoma of the esophagus.
Expression of granulocyte colony-stimulating factor receptor and platelet-derived endothelial cell growth factor in oral and oropharyngeal precancerous lesions.
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers.
Expression of platelet-derived endothelial cell growth factor in bladder carcinoma.
Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors.
Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma.
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in cervical intraepithelial neoplasia.
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions.
Expression of pyrimidine nucleoside phosphorylase mRNA plays an important role in the prognosis of patients with oesophageal cancer.
Expression of thymidine phosphorylase and angiogenesis in human ovarian tumor.
Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics.
Expression of thymidine phosphorylase and VEGF in esophageal squamous cell carcinoma.
Expression of thymidine phosphorylase as an effect prediction factor for uterine cervical squamous cell carcinoma after radiotherapy: an immunohistochemical study.
Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder.
Expression of thymidine phosphorylase in human gastric carcinoma.
Expression of thymidine phosphorylase in primary human renal cell carcinoma by ELISA method.
Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: implication for method to detect expression of these molecules in clinic.
Expressions of thymidine phosphorylase (dThdPase) and vascular endothelial growth factor on angiogenesis in intestinal-type gastric carcinoma.
Frequent expression of thymidine phosphorylase in Epstein-Barr virus-associated gastric carcinoma of diffuse type.
Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma.
Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for oral squamous cell carcinoma.
High level concentration of pyrimidine nucleoside phosphorylase in esophageal squamous cell carcinoma but no correlation with clinicopathological parameters.
High levels of thymidine phosphorylase as an independent prognostic factor in renal cell carcinoma.
Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: the influence of neoadjuvant treatment.
IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma.
Immunohistochemical expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in squamous cell carcinoma of the esophagus.
Immunohistochemical localization of thymidine phosphorylase in gastric cancer: is there a role of the differential expression in tumor cells and associated stromal cells?
Impact of thymidine phosphorylase-expressing macrophages for surgical margin in partial nephrectomy.
Increased expression of platelet-derived endothelial cell growth factor in human hepatocellular carcinomas correlated with high Edmondson grades and portal vein tumor thrombosis.
Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha.
Induction of thymidine phosphorylase expression and enhancement of Furtulon sensitivity by Taxol in a human ovarian carcinoma cell line.
Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
Influence of platelet-derived endothelial cell growth factor/thymidine phosphorylase on the cell cycle in head and neck squamous cell carcinoma in vitro.
Localization of thymidine phosphorylase expression in colorectal carcinoma tissues by in situ RT-PCR assay.
Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas.
Neoangiogenesis in patients with gastric carcinoma in relation to the expression of vascular endothelial growth factor and thymidine phosphorylase.
No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix.
Over expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in patients with interstitial cystitis and bladder carcinoma.
Papers to Appear in Forthcoming Issues
Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy.
PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis.
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.
Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver.
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.
Platelet-derived endothelial cell growth factor in keratinizing-type squamous cell uterine cervical cancer.
Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Poor Prognosis Associated with High Levels of Thymidine Phosphorylase and Thrombocytosis in Patients with Renal Cell Carcinoma.
Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase.
Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor.
Predictive value of thymidine phosphorylase in gastric carcinoma.
Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.
Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture.
Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma.
Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma.
Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma.
Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma.
Prognostic Significance of Thymidine Phosphorylase in Superficial Bladder Carcinoma.
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Pyrimidine nucleoside phosphorylase-activity and biological characteristics of breast-cancer.
Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma.
Regulation and novel action of thymidine phosphorylase in non-small cell lung cancer: crosstalk with Nrf2 and HO-1.
Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells.
Reliability of platelet-derived endothelial cell growth factor as a prognostic factor for oral and oropharyngeal carcinomas.
Role of tumor angiogenesis in gallbladder carcinoma: with special reference to thymidine phosphorylase.
Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5'-deoxy-5-fluorouridine.
Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites.
Significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor in carcinoma of the papilla of Vater.
TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma.
The activity and expression of thymidine phosphorylase in human solid tumours.
The effect of neoadjuvant therapy on the 5-fluorouracil metabolic and relative enzymes of oral squamous cell carcinoma.
The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma.
The expression of thymidine phosphorylase suppresses spontaneous apoptosis of cancer cells in esophageal squamous cell carcinoma.
The expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor is correlated to angiogenesis in breast cancer.
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
The predictive value of p53, Ki-67 and angiogenetic factors in primary hypopharyngeal carcinoma.
The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus.
The role of thymidine phosphorylase expression in the invasiveness of gastric carcinoma.
The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells.
The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget's disease of the vulva and breast.
The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells.
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Thymidine Kinase 1 and Thymidine Phosphorylase Expression in Non-small Cell Lung Carcinoma in Relation to Angiogenesis and Proliferation.
Thymidine phosphorylase activity in nonsmall cell lung carcinoma tissues.
Thymidine phosphorylase activity in renal cell carcinoma: relationship between histological parameters and chemosensitivity to fluorouracil-related drugs.
Thymidine phosphorylase and angiogenesis in early stage esophageal squamous cell carcinoma.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil.
Thymidine phosphorylase as a prognostic factor in renal cell carcinoma.
Thymidine phosphorylase expression causes both the increase of intratumoral microvessels and decrease of apoptosis in human esophageal carcinomas.
Thymidine phosphorylase expression in gastric carcinoma as a marker for metastasis.
Thymidine phosphorylase expression in human colorectal mucosa, adenoma and carcinoma: role of p53 expression.
Thymidine phosphorylase expression in invasive carcinoma: correlations with clinicopathologic variables and in vitro chemosensitivity to 5-fluorouracil.
Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis.
Thymidine phosphorylase expression in oral squamous cell carcinoma.
Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis.
Thymidine phosphorylase expression in tumor stroma of uterine cervical carcinomas: histological features and microvessel density.
Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas.
Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma.
Thymidine phosphorylase expression results in a decrease in apoptosis and increase in intratumoral microvessel density in human gastric carcinomas.
Thymidine phosphorylase in human esophageal squamous cell carcinoma.
Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors.
Thymidine phosphorylase levels as a prognostic factor in renal cell carcinoma.
Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil.
Thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma.
Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma.
Thymidine phosphorylase/platelet-derived endothelial cell growth factor is upregulated in advanced solid types of gastric cancer.
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma.
Transcriptional expression of the genes implicated in angiogenesis and tumor invasion in cervical carcinomas.
Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma.
Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum.
Tumor angiogenesis as an independent prognostic factor after extended radical esophagectomy for invasive squamous cell carcinoma of the esophagus.
Variations in the expression of platelet-derived endothelial cell growth factor in human colorectal polyps.
Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas.
[Activities of pyrimidine nucleoside phosphorylase in brain tumors and antitumor effect of 5'-DFUR]
[Effect of thymidine phosphorylase cDNA transfection on the inhibition of human colon carcinoma cell line by 5'-deoxy-5-fluorouridine].
[Improved sensitivity of gastric carcinoma cells to fluorouracil-related drugs by transfection of thymidine phosphorylase gene].
[Influence of interferon-?2a on thymidine phosphorylase expression and anticancer activity of 5'-deoxy-fluorouridine in human colon carcinoma cell lines LOVO and SW480].
[Long-term outcome of preoperative chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR) for gastric cancer]
[Prognostic effect of PyNPase (pyrimidine nucleoside phosphorylase) activity in breast cancer]
[Study of PyNPase activity in patients with gastric cancer--the association with preoperative IAP values]
[The alteration of PyNPase activity in breast cancers due to preoperative oral administration of 5'-DFUR]
[The expressions of TP, MK and CD105 in laryngeal squamous cell carcinoma and their clinical significance]
[The mRNA expression of platelet-derived endothelial cell growth factor of bladder transitional cell carcinoma and its relation to invasiveness]
[Use of the study of DNA metabolism enzyme activities as a test system in the treatment of breast cancer]
Carcinoma in Situ
Angiogenic growth factors in preinvasive breast disease.
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in cervical intraepithelial neoplasia.
Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis.
Carcinoma, Adenosquamous
Different angiogenic pathways in human cervical cancers.
Carcinoma, Ductal
Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast.
HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer.
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives.
The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget's disease of the vulva and breast.
Thymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breast.
Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast.
Carcinoma, Endometrioid
Angiogenesis and endometrial cancer.
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in ovarian cancers.
Carcinoma, Hepatocellular
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients.
Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment.
Effects of 5'-DFUR and lentinan on cytokines and PyNPase against AH66 ascites hepatoma in rats.
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.
High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection.
Increased expression of platelet-derived endothelial cell growth factor in human hepatocellular carcinomas correlated with high Edmondson grades and portal vein tumor thrombosis.
Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice.
Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver.
Prognostic value of thymidine phosphorylase activity in liver tissue adjacent to hepatocellular carcinoma.
The significance of thymidine phosphorylase activity in hepatocellular carcinoma and chronic diseased livers: a special reference to liver fibrosis and multicentric tumor occurrence.
Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma.
Thymidine phosphorylase activity in liver tissue and its correlation with multifocal occurrence of hepatocellular carcinomas.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer.
Thymidine phosphorylase promotes malignant progression in hepatocellular carcinoma through pentose Warburg effect.
Thymidine phosphorylase promotes metastasis and serves as a marker of poor prognosis in hepatocellular carcinoma.
Transfection of thymidine phosphorylase cDNA to human hepatocellular carcinoma cells enhances sensitivity to fluoropyrimidine but augments endothelial cell migration.
[Activities of pyrimidine nucleoside phosphorylase in brain tumors and antitumor effect of 5'-DFUR]
[Expression rates of three angiogenic factors in hepatocellular carcinoma and their relation with microvessel density and portal vein tumor thrombosis]
[Interferon alpha enhances the sensitivity of SMMC-7721 hepatocellular carcinoma cells to 5'-deoxy-5-fluorouridine related to up-regulation of thymidine phosphorylase]
[Interferon-alpha upregulates thymidine phosphorylase expression via JAK-STAT transcriptional activation and mRNA stabilization in human hepatocellular carcinoma SMMC-7721 cells]
[Up-regulation of thymidine phosphorylase and anti-angiogenesis by interferon alpha in human hepatocellular carcinoma cell line and xenograft]
Carcinoma, Intraductal, Noninfiltrating
Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast.
Does thymidine phosphorylase correlate with angiogenesis in intraductal carcinoma of the breast?
The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget's disease of the vulva and breast.
Thymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breast.
Carcinoma, Large Cell
Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines.
Carcinoma, Lewis Lung
Comparative antitumor activity and intestinal toxicity of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine.
Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5'-deoxy-5-fluorouridine.
Carcinoma, Non-Small-Cell Lung
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.
Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancer.
Metformin Induces Cytotoxicity by Down-Regulating Thymidine Phosphorylase and Excision Repair Cross-Complementation 1 Expression in Non-Small Cell Lung Cancer Cells.
Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer.
Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients.
Regulation and novel action of thymidine phosphorylase in non-small cell lung cancer: crosstalk with Nrf2 and HO-1.
Thymidine Kinase 1 and Thymidine Phosphorylase Expression in Non-small Cell Lung Carcinoma in Relation to Angiogenesis and Proliferation.
Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.
Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.
Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues.
Up-regulation of ERK1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small cell lung cancer cells.
Carcinoma, Ovarian Epithelial
Expression of the thymidine phosphorylase gene in epithelial ovarian cancer.
Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor.
Expression of thymidine phosphorylase in epithelial ovarian cancer: correlation with angiogenesis, apoptosis, and ultrasound-derived peak systolic velocity.
Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer.
Papers to Appear in Forthcoming Issues
Papers to appear in forthcoming issues
Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer.
Relationship between the expression of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase and survival in epithelial ovarian cancer.
Role of lymphangiogenesis in epithelial ovarian cancer.
Thymidylate synthase expression in epithelial ovarian cancer: relationship with thymidine phosphorylase expression and prognosis.
Carcinoma, Pancreatic Ductal
Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival.
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives.
Carcinoma, Papillary
Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum.
Carcinoma, Renal Cell
Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase.
Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma.
Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Expression of thymidine phosphorylase in primary human renal cell carcinoma by ELISA method.
High levels of thymidine phosphorylase as an independent prognostic factor in renal cell carcinoma.
Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: the influence of neoadjuvant treatment.
Impact of thymidine phosphorylase-expressing macrophages for surgical margin in partial nephrectomy.
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.
Poor Prognosis Associated with High Levels of Thymidine Phosphorylase and Thrombocytosis in Patients with Renal Cell Carcinoma.
Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma.
Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma.
Thymidine phosphorylase activity in renal cell carcinoma: relationship between histological parameters and chemosensitivity to fluorouracil-related drugs.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil.
Thymidine phosphorylase as a prognostic factor in renal cell carcinoma.
Thymidine phosphorylase levels as a prognostic factor in renal cell carcinoma.
Thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma.
Carcinoma, Small Cell
Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines.
Carcinoma, Squamous Cell
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer.
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Coexpression of cyclooxygenase-2 and thymidine phosphorylase as a prognostic indicator in patients with FIGO stage IIB squamous cell carcinoma of uterine cervix treated with radiotherapy and concurrent chemotherapy.
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Differences and relationships of thymidine phosphorylase expression in tumor-associated macrophages and cancer cells in squamous cell carcinoma of the esophagus.
Different angiogenic pathways in human cervical cancers.
Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines.
Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.
Expression of basic fibroblast growth factor is associated with a good outcome in patients with squamous cell carcinoma of the esophagus.
Expression of granulocyte colony-stimulating factor receptor and platelet-derived endothelial cell growth factor in oral and oropharyngeal precancerous lesions.
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers.
Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics.
Expression of thymidine phosphorylase as an effect prediction factor for uterine cervical squamous cell carcinoma after radiotherapy: an immunohistochemical study.
Influence of platelet-derived endothelial cell growth factor/thymidine phosphorylase on the cell cycle in head and neck squamous cell carcinoma in vitro.
Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma.
Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy.
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.
Platelet-derived endothelial cell growth factor in keratinizing-type squamous cell uterine cervical cancer.
Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture.
Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma.
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Reliability of platelet-derived endothelial cell growth factor as a prognostic factor for oral and oropharyngeal carcinomas.
Structural properties of 3.0 kb and 3.2 kb transcripts encoding platelet-derived endothelial cell growth factor/thymidine phosphorylase in A431 cells.
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus.
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Thymidine phosphorylase expression causes both the increase of intratumoral microvessels and decrease of apoptosis in human esophageal carcinomas.
Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis.
Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma.
Thymidine phosphorylase in human esophageal squamous cell carcinoma.
Carcinoma, Transitional Cell
Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.
Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer.
[The mRNA expression of platelet-derived endothelial cell growth factor of bladder transitional cell carcinoma and its relation to invasiveness]
Cardiovascular Diseases
Thymidine phosphorylase: A potential new target for treating cardiovascular disease.
Cervical Intraepithelial Neoplasia
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in cervical intraepithelial neoplasia.
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.
[Immunohistochemical study of thymidine phosphorylase in uterine cervical intraepithelial neoplasia]
[Ki-67 expression, thymidine phosphorylase and PTEN in intraepithelial cervical carcinoma].
Cholangiocarcinoma
Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series.
Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.
Interrelationship of platelet-derived endothelial cell growth factor, liver macrophages, and tumor microvessel density in patients with cholangiocellular carcinoma.
The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.
Thymidine phosphorylase promotes angiogenesis and tumour growth in intrahepatic cholangiocarcinoma.
Choroidal Neovascularization
Subconjunctival doxifluridine administration suppresses rat choroidal neovascularization through activated thymidine phosphorylase.
Coinfection
Mycoplasma pneumoniae thymidine phosphorylase.
Colitis, Ulcerative
Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease.
Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease.
Colonic Neoplasms
Anticancer effectiveness of polymeric drug nanocarriers on colorectal cancer cells.
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
Changes over time in thymidine phosphorylase and dihydropyrimidine dehydrogenase when colon cancer samples are left at room temperature.
Correlation between expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) and microvessel density in early-stage human colon carcinomas.
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Differential expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) in nonpolypoid and polypoid lesions of the colon.
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Enhancement of the anti-tumor effect of 5'-deoxy-5-fluorouridine by transfection of thymidine phosphorylase gene into human colon cancer cells.
Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease.
Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Logistic regression model of the clinical response to 5-fluorouracil based chemotherapy for metastatic colorectal cancer patients.
Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells.
Platelet-derived endothelial cell growth factor mediates Rho-associated coiled-coil domain kinase messenger RNA expression and promotes cell motility.
Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues.
Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers.
PyNPase expression in human colon cancer.
Pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase indicate chemosensitivity of human colon cancer specimens to doxifluridine and 5-fluorouracil, respectively.
Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.
Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells.
Significance of expression of pyrimidine metabolizing genes in colon cancer.
Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer.
The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion.
The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase.
Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.
[Analysis of the salvage synthesis within biosynthesis of nucleic acid route in colon cancer]
[Effects of expression of thymidine phosphorylase induced by gamma-interferon on regulation of antineoplastic activity of fluorouracil on colonic cancer]
[Enhanced anticancer effects of 5'-DFUR on colorectal cancer cell lines SW480 and LOVO by transfection with thymidine phosphorylase cDNA].
[Significance of 5'-deoxy-5-fluorouridine (5'-DFUR) administration before surgery for advanced gastric and colonic cancers--activity of pyrimidine nucleoside phosphorylase (PyNPase) and serum immunosuppressive acidic protein (IAP)]
[Thymidine phosphorylase is correlated with DPD in colon cancer]
Colorectal Neoplasms
5-Fluorouracil-related gene expression in hepatic artery infusion-treated patients with hepatic metastases from colorectal carcinomas.
5-Fluorouracil-related gene expression in primary sites and hepatic metastases of colorectal carcinomas.
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
Association between p53 expression and Bcl-2, P-glycoprotein, topoisomerase II alpha, thymidylate synthase and thymidine phosphorylase as potential therapeutic targets in colorectal cancer patients.
Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer.
Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
Clinical significance of pyrimidine nucleoside phosphorylase in colorectal carcinoma.
Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.
Clinicopathological significance of vascular endothelial growth factor, thymidine phosphorylase and microvessel density in colorectal cancer.
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Comparative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in gastric and colorectal cancers.
Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue.
Correlation between malignancy grade and p53 gene in relation to thymidine phosphorylase activity in colorectal cancer patients.
Correlation of thymidine phosphorylase staining and the Ki-67 labeling index to clinicopathologic factors and hepatic metastasis in patients with colorectal cancer.
Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.
Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines.
Development and characterization of 1C6-203, a new monoclonal antibody specific to human thymidine phosphorylase.
Effects of Platelet-Derived Endothelial Cell Growth Factor and Doppler Perfusion Index in Patients with Colorectal Hepatic Metastases.
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Endogenous gamma-interferon activates thymidine phosphorylase in colorectal cancer tissue.
Enhancement of the anti-tumor effect of 5'-deoxy-5-fluorouridine by transfection of thymidine phosphorylase gene into human colon cancer cells.
Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer.
Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer.
Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma.
Expression of pyrimidine nucleoside phosphorylase (PyNPase) in colorectal cancer.
Expression of thymidine phosphorylase by macrophages in colorectal cancer tissues.
Fatty liver suppressed the angiogenesis in liver metastatic lesions.
Fluorescence and computational studies of thymidine phosphorylase affinity toward lipidated 5-FU derivatives.
Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis.
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma.
Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase.
Integrated safety summary for trifluridine/tipiracil (TAS-102).
Interferon alpha and 5'-deoxy-5-fluorouridine in colon cancer: effects as single agents and in combination on growth of xenograft tumours.
Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer.
Localization of thymidine phosphorylase expression in colorectal carcinoma tissues by in situ RT-PCR assay.
Localization of thymidine phosphorylase in advanced gastric and colorectal cancer.
Localization of thymidine phosphorylase in breast cancer tissue.
Methylenetetrahydrofolate reductase C677T is not associated with expression of pyrimidine metabolic enzyme genes in colorectal cancer.
Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Neoplastic stroma and epithelium show up-regulation of platelet-derived endothelial cell growth factor/thymidine phosphorylase in colorectal carcinomas but not adenomas.
Occurrence of hematogenous metastasis and serum levels of thymidine phosphorylase in colorectal cancer.
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Platelet-derived endothelial cell growth factor expression is an independent prognostic factor in colorectal cancer patients after curative surgery.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase inhibitor augments radiotherapeutic efficacy in experimental colorectal cancer.
Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
Prediction of 5'-deoxy-5-fluorouridine sensitivity in colorectal cancer cases by thymidine phosphorylase activity and preliminary identification of susceptibility related genes.
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Predictive role of thymidine phosphorylase expression in patients with colorectal cancer and its association with angiogenesis-related proteins and extracellular matrix components.
Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Progesterone receptor positive colorectal tumors have lower thymidine phosphorylase expression: an immunohistochemical study.
Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Prognostic significance of the serum thymidine phosphorylase levels in venous blood drainage specimens in patients with colorectal cancer.
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
PyNPase expression in human colon cancer.
Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer.
Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil.
Research development of the relationship between thymidine phosphorylase expression and colorectal carcinoma.
Review on TAS-102 development and its use for metastatic colorectal cancer.
Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen.
Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma.
Specific enhanced expression of platelet-derived endothelial cell growth factor in submucosa of human colorectal cancer.
Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts.
The activities of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer depend on where the sample is taken.
The correlation of thymidine phosphorylase activity with the expression of interleukin 1 alpha, interferon alpha and interferon gamma in human colorectal carcinoma.
The dual role of thymidine phosphorylase in cancer development and chemotherapy.
The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas.
The relationship between clinicopathological factors and the reduction of pyrimidine nucleoside phosphorylase activity after preoperative administration of 5'-deoxy-5-fluorouridine.
The significance of thymidine phosphorylase expression in colorectal cancer.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of t3 human colorectal carcinoma.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer.
Thymidine phosphorylase expressed in macrophages enhances antitumor effect of 5'-deoxy-5-fluorouridine on human colorectal carcinoma cells.
Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients.
Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5-fluorouracil-based chemotherapy: A meta-analysis.
Thymidine phosphorylase expression in human colorectal mucosa, adenoma and carcinoma: role of p53 expression.
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas.
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer.
Thymidine Phosphorylase Gene Expression in Stage III Colorectal Cancer.
Thymidine phosphorylase mRNA expression may be a predictor of response to post-operative adjuvant chemotherapy with S-1 in patients with stage III colorectal cancer.
Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.
Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?
Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis.
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
Thymidylate Synthase, Thymidine Phosphorylase, VEGF and p53 Protein Expression in Primary Colorectal Cancer for Predicting Response to 5-fluorouracil-based Chemotherapy.
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
Tumor growth pattern and thymidine phosphorylase expression are related with the risk of hematogenous metastasis in patients with Astler Coller B1/B2 colorectal carcinoma.
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
[Antitumor effect of 5'-DFUR and PyNPase activity in colorectal cancer]
[Clinicopathological significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced colorectal cancer]
[Dihydropyrimidine dehydrogenase and thymidine phosphorylase as a prognostic factor of colorectal cancer patients].
[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]
[Effect on 5'-deoxy-5-fluorouridine (5'-DFUR) of pyrimidine nucleoside phosphorylase (PyNPase), matrix metalloprotease and serum IAP values. Hokuriku Colorectal Cancer Chemotherapy Study Group]
[Enhanced anticancer effects of 5'-DFUR on colorectal cancer cell lines SW480 and LOVO by transfection with thymidine phosphorylase cDNA].
[Expression of mRNA levels of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in diffusely infiltrating colorectal cancer]
[Expression of thymidine phosphorylase in human colorectal carcinoma and its clinical significance]
[Expression of thymidine phosphorylase in primary colorectal cancer and liver metastasis-relationship between mRNA levels in cancer cells and protein levels in cancerous tissue]
[Expression of vascular growth factors in intestinal tissues in colorectal carcinoma patients with schistosomiasis japonica].
[Immunohistochemical staining of thymidine phosphorylase in primary colorectal carcinoma and metastases]
[Prognosis and efficacy of postoperative adjuvant chemotherapy in colorectal cancer correlates with nucleic acid metabolizing enzymes]
[PyNPase activity in primary and metastatic colorectal cancer]
[PyNPase expression and cancer progression in the colorectum]
[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]
[Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration]
[Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer]
[The influence of Thymidine Phosphorylase genetic variation on clinical outcomes and safety of colorectal cancer patients received adjuvant chemotherapy after R0 resection].
[The relation between pyrimidine nucleoside phosphorylase (PyNPase) activity in colorectal cancer tissues and pathological effects]
[The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].
[Thymidine phosphorylase expressed in monocyte-macrophages enhanced anticancer effect of 5'-deoxy-5-fluorouridine on colorectal carcinoma cells]
[Thymidine phosphorylase expression in hepatic metastasis from colorectal carcinoma]
[Transfection of thymidine phosphorylase cDNA with lentiviral vector enhances the anticancer effect of 5'-deoxy-5-fluorouridine on colorectal cancer cell lines HT29 and LS174T].
[Tumoral levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in elderly colorectal cancer patients]
COVID-19
Thymidine Phosphorylase Is Increased in COVID-19 Patients in an Acuity-Dependent Manner.
Crohn Disease
Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease.
Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease.
Cystadenocarcinoma, Serous
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in ovarian cancers.
Cystadenoma
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives.
Cystitis, Interstitial
Over expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in patients with interstitial cystitis and bladder carcinoma.
Overexpression of platelet-derived endothelial cell growth factor (PD-ECGF) factor/thymidine phosphorylase (TP) in interstitial cystitis.
Cysts
Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer.
Diabetes Mellitus
Thymidine phosphorylase participates in platelet signaling and promotes thrombosis.
Diffuse Cerebral Sclerosis of Schilder
Mitochondrial syndromes with leukoencephalopathies.
Distal Myopathies
Primary muscle diseases in Thammasat University Hospital: muscle biopsy study of 12 cases.
Dysarthria
Inherited peripheral neuropathies due to mitochondrial disorders.
[Peripheral neuropathies due to mitochondrial disorders]
Endometrial Hyperplasia
Thymidine phosphorylase expression in normal and hyperplastic endometrium.
Endometrial Neoplasms
A role of thymidine phosphorylase and P53 tissue protein expression in biology of endometrial cancer.
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in endometrial cancer.
Clinical implications of expression of ETS-1 related to angiogenesis in uterine endometrial cancers.
Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers.
Co-expression of vascular endothelial growth factor and thymidine phosphorylase in endometrial cancer.
Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase.
Effects of various steroids on platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA expression in uterine endometrial cancer cells.
Evaluation of tumor angiogenesis and thymidine phosphorylase tissue expression in patients with endometrial cancer.
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers.
Immunohistochemical expression of thymidine phosphorylase in human endometrial cancer.
Papers to Appear in Forthcoming Issues
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
The cytosol activity of thymidine phosphorylase in endometrial cancer.
Thymidine phosphorylase expression in endometrial carcinomas.
Thymidine phosphorylase expression in tumor-infiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer.
Thymidine phosphorylase expression is predominantly observed in stroma of well-differentiated adenocarcinoma of endometrium and correlates with a frequency of vascular involvement.
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer.
[Immunohistochemistry and activities of thymidine phosphorylase in the tissues of uterine cervical and endometrial carcinomas]
[The thymidine phosphorylase as the platelet-derived endothelial cell growth factor of endometrial cancer]
Endometriosis
Angiogenesis in endometriosis and angiogenic factors.
Angiogenesis in ovarian clear cell carcinoma and its relation to endometriosis.
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) related to angiogenesis in ovarian endometriosis.
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Esophageal Neoplasms
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Esophageal Squamous Cell Carcinoma
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Expression of thymidine phosphorylase and VEGF in esophageal squamous cell carcinoma.
High level concentration of pyrimidine nucleoside phosphorylase in esophageal squamous cell carcinoma but no correlation with clinicopathological parameters.
Immunohistochemical expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in squamous cell carcinoma of the esophagus.
Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma.
Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma.
TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma.
The expression of thymidine phosphorylase suppresses spontaneous apoptosis of cancer cells in esophageal squamous cell carcinoma.
Thymidine phosphorylase and angiogenesis in early stage esophageal squamous cell carcinoma.
Thymidine phosphorylase in human esophageal squamous cell carcinoma.
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Fanconi Anemia
Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes.
Fatty Liver
Fatty liver suppressed the angiogenesis in liver metastatic lesions.
Nutrition Therapy for Mitochondrial Neurogastrointestinal Encephalopathy with Homozygous Mutation of the TYMP Gene.
Fibroadenoma
[Distributions of pyrimidine nucleoside phosphorylase (PyNPase) in tissues of benign and malignant mammary diseases--immunohistochemical observations]
Gallbladder Neoplasms
Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.
Gastritis
Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma.
Gastrointestinal Neoplasms
Comparison of the pyrimidine nucleoside phosphorylase activity in human tumors and normal tissues.
Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine.
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer.
Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.
Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue.
Preoperative endoscopic analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in gastrointestinal cancer.
Thymidine phosphorylase gene variant, platelet counts and survival in gastrointestinal cancer patients treated by fluoropyrimidines.
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
[The analysis of thymidine phosphorylase examined by ELISA in bladder cancer]
Genetic Diseases, Inborn
Assessment of stability, toxicity and immunogenicity of new polymeric nanoreactors for use in enzyme replacement therapy of MNGIE.
Glaucoma, Neovascular
Expression of thymidine phosphorylase in choroidal malignant melanoma associated with neovascular glaucoma.
Glioblastoma
Angiogenic effect of thymidine phosphorylase on macrophages in glioblastoma multiforme.
Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in vitro Toxicity, and Impact on Human Glioblastoma Cancer.
Evaluation of Thymidine Phosphorylase Inhibitors in Glioblastoma and Their Capacity for Temozolomide Potentiation.
Glycation of glutamate cysteine ligase by 2-deoxy-d-ribose and its potential impact on chemoresistance in glioblastoma.
Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells.
Stromal angiogenesis in human glioma: a role of platelet-derived endothelial cell growth factor.
[Localization of platelet-derived endothelial cell growth factor in human glioblastoma and meningioma]
Glioma
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.
Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells.
Intracavitary chemotherapy with 5-fluoro-2'-deoxyuridine (FdUrd) in malignant brain tumors.
Macrophage infiltration-associated thymidine phosphorylase expression correlates with increased microvessel density and poor prognosis in astrocytic tumors.
Stromal angiogenesis in human glioma: a role of platelet-derived endothelial cell growth factor.
Glomerulonephritis
Upregulation of thymidine phosphorylase in chronic glomerulonephritis and its role in tubulointerstitial injury.
Head and Neck Neoplasms
Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
Influence of platelet-derived endothelial cell growth factor/thymidine phosphorylase on the cell cycle in head and neck squamous cell carcinoma in vitro.
Microvessel density, thymidine phosphorylase expression and resistance of head and neck cancer to chemo-radiotherapy.
Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation.
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Hearing Loss
Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE).
Heart Defects, Congenital
Angiogenic biomarkers in children with congenital heart disease: possible implications.
Heart Diseases
Exploring the protective effects of schizandrol A in acute myocardial ischemia mice by comprehensive metabolomics profiling integrated with molecular mechanism studies.
Hemangioma, Capillary
[The role of PD-ECGF and VEGF in proliferative and involuted mechanism of the infantile capillary hemangiomas].
Hepatitis
Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver.
Thymidine phosphorylase expression in patients with chronic viral hepatitis.
Hepatitis C
Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma.
Hepatitis, Chronic
Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients.
Herpes Simplex
5-(Trifluoromethyl)-beta-l-2'-deoxyuridine, the L-enantiomer of trifluorothymidine: stereospecific synthesis and antiherpetic evaluations.
The in vitro evaluation of nucleoside analogues as probes for use in the noninvasive diagnosis of herpes simplex encephalitis.
Histiocytoma, Malignant Fibrous
Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase.
Hodgkin Disease
Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL).
Platelet-derived endothelial cell growth factor/thymidine phosphorylase immunohistochemical expression in lymphoid tissue and lymphoid malignancies.
Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma.
Hyperlipidemias
Nutrition Therapy for Mitochondrial Neurogastrointestinal Encephalopathy with Homozygous Mutation of the TYMP Gene.
Hypersensitivity
Expression of platelet-derived endothelial cell growth factor and vascularity in the nasal mucosa from allergic rhinitis.
The role of thymidine phosphorylase in the pathogenesis of allergic rhinitis.
Infections
Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma.
[Thymine- and thymidine-dependence of Yersinia pestis mutants with altered thymidylate synthetase]
Inflammatory Bowel Diseases
Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease.
Influenza, Human
The next ten stories on antiviral drug discovery (part E): Advents, Advances, and Adventures.
Intestinal Pseudo-Obstruction
Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion.
Kidney Neoplasms
Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story.
[The correlation between thymidine phosphorylase activity of renal cancer cells and the chemosensitivity to 5-FU and 5'-DFUR]
Leiomyoma
Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma.
Expression of thymidine phosphorylase in uterine sarcoma and uterine leiomyoma: association with microvessel density and Doppler blood flow analysis.
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
The activity of thymidine phosphorylase obtained from human uterine leiomyomas and studied in the presence of pyrimidine derivatives.
[Growth mechanisms and morphological structural features of large uterine leiomyoma].
Leiomyosarcoma
Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma.
Leukemia
In vitro and in vivo studies of a promising antileukemic thymidine analogue, 5-hydroxymethyl-2' deoxyuridine.
Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors.
[Activities of enzymes converting 5-fluorouracil to 5-fluorouridine-5' monophosphate and 5-fluorodeoxyuridine-5' monophosphate in subcultured cell lines and solid tumor tissues]
Leukoencephalopathies
Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE).
Leukoencephalopathy in Mitochondrial Neurogastrointestinal Encephalomyopathy-Like Syndrome with Polymerase-Gamma Mutations.
Mitochondrial neurogastrointestinal encephalomyopathy associated with progressive hearing loss.
Pitfalls in diagnosing mitochondrial neurogastrointestinal encephalomyopathy.
Leukoplakia, Oral
Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma.
Lichen Sclerosus et Atrophicus
Role of angiogenesis in benign, premalignant and malignant vulvar lesions.
Liver Cirrhosis
The significance of thymidine phosphorylase activity in hepatocellular carcinoma and chronic diseased livers: a special reference to liver fibrosis and multicentric tumor occurrence.
Liver Diseases
Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients.
Significance of thymidine phosphorylase in HCC with chronic liver disease for long-term postoperative recurrence.
Liver Neoplasms
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer.
Thymidine phosphorylase promotes angiogenesis and tumour growth in intrahepatic cholangiocarcinoma.
[Enzymatic conversion of tegafur in human tumor tissue]
[The expression of platelet-derived endothelial cell growth factor in liver cancer]
Lung Neoplasms
bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer.
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.
Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival.
Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549.
Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancer.
Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer.
Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cells.
Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer.
Metformin Induces Cytotoxicity by Down-Regulating Thymidine Phosphorylase and Excision Repair Cross-Complementation 1 Expression in Non-Small Cell Lung Cancer Cells.
Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer.
Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer.
Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients.
Regulation and novel action of thymidine phosphorylase in non-small cell lung cancer: crosstalk with Nrf2 and HO-1.
Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.
Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.
Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues.
Thymidylate Synthase, Dihydropyrimidine Dehydrogenase, Thymidine Phosphorylase, Orotate Phosphoribosyltransferase mRNA Expression in Lung Cancer Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration - A Pilot Study.
Up-regulation of ERK1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small cell lung cancer cells.
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
[Immunohistochemical localization of thymidine phosphorylase in primary lung cancer]
Lymphadenopathy
Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma.
Lymphatic Metastasis
Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer.
Clinical significance of pyrimidine nucleoside phosphorylase in colorectal carcinoma.
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.
Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma.
Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma.
Correlation between expression levels of thymidine phosphorylase (dThdPase) and clinical features in human gastric carcinoma.
Expression of angiogenic factors and tumor progression in human neuroblastoma.
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions.
Expression of pyrimidine nucleoside phosphorylase mRNA plays an important role in the prognosis of patients with oesophageal cancer.
Expression of thymidine phosphorylase in human gastric carcinoma.
High level concentration of pyrimidine nucleoside phosphorylase in esophageal squamous cell carcinoma but no correlation with clinicopathological parameters.
PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis.
Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer.
Platelet-derived endothelial cell growth factor mediates Rho-associated coiled-coil domain kinase messenger RNA expression and promotes cell motility.
Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer.
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Reliability of platelet-derived endothelial cell growth factor as a prognostic factor for oral and oropharyngeal carcinomas.
The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus.
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
Up-regulated pyrimidine nucleoside phosphorylase in breast carcinoma correlates with lymph node metastasis.
[Malignancy of gastric cancer analyzed by the expression of thymidine phosphorylase]
[PyNPase activity in primary and metastatic colorectal cancer]
Lymphoma
Platelet-derived endothelial cell growth factor/thymidine phosphorylase immunohistochemical expression in lymphoid tissue and lymphoid malignancies.
Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors.
Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma.
Lymphoma, B-Cell
Thymidine phosphorylase expression in B-cell lymphomas and its significance: a new prognostic marker?
Lymphoma, Non-Hodgkin
Pyrimidine and purine activities in non-Hodgkin's lymphoma. Correlation with histological status and survival.
Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma.
Lymphoma, T-Cell
Inhibition of thymidine phosphorylase (PD-ECGF) from SD-lymphoma by phosphonomethoxyalkyl thymines.
Structural diversity of nucleoside phosphonic acids as a key factor in the discovery of potent inhibitors of rat T-cell lymphoma thymidine phosphorylase.
Melanoma
Co-expression of thymidine phosphorylase and heme oxygenase-1 in macrophages in human malignant vertical growth melanomas.
Differential metabolism of thymidine in human lymphoid and melanoma cells in vitro.
Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.
Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma.
Expression of thymidine phosphorylase in choroidal malignant melanoma associated with neovascular glaucoma.
Immunohistochemical expression of platelet growth factor and vascular endothelial growth factor in patients with melanoma with and without redness (Brenner sign).
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
Meningeal Carcinomatosis
Intracavitary chemotherapy with 5-fluoro-2'-deoxyuridine (FdUrd) in malignant brain tumors.
Intrathecal 5-fluoro-2'-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study.
Meningioma
Stromal angiogenesis in human glioma: a role of platelet-derived endothelial cell growth factor.
[Localization of platelet-derived endothelial cell growth factor in human glioblastoma and meningioma]
Mitochondrial Diseases
Frequency of mitochondrial defects in patients with chronic intestinal pseudo-obstruction.
Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion.
Thymidine phosphorylase deficiency causes MNGIE: an autosomal recessive mitochondrial disorder.
Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder.
Mitochondrial Myopathies
POG01 Anti-thymidine phosphorylase antibodies in the diagnosis of mitochondrial neurogastrointestinal encephalomyopathy.
Mouth Neoplasms
Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma.
Muscle Weakness
Mitochondrial neurogastrointestinal encephalomyopathy associated with progressive hearing loss.
Muscular Diseases
Primary muscle diseases in Thammasat University Hospital: muscle biopsy study of 12 cases.
Myasthenia Gravis
Transient clinical improvement of a mitochondrial neurogastrointestinal encephalomyopathy-like syndrome after allogeneic haematopoietic stem cell transplantation.
Mycosis Fungoides
Expression of thymidine phosphorylase in lymph nodes involved with mycosis fungoides and sézary syndrome.
Myocardial Infarction
Myocardial expression of PDECGF is associated with extracellular matrix remodeling in experimental myocardial infarction in rats.
Myocardial Ischemia
Gene therapy for chronic myocardial ischemia using platelet-derived endothelial cell growth factor in dogs.
Myoma
The activity of thymidine phosphorylase in the uterine myomas and the myometrium in perimenopausal women.
Myxoma
Significance of monocyte chemotactic protein-1 and thymidine phosphorylase in angiogenesis of human cardiac myxoma.
Nasopharyngeal Carcinoma
Epstein-Barr virus latent membrane protein 1 induces the chemotherapeutic target, thymidine phosphorylase, via NF-kappaB and p38 MAPK pathways.
Heterogeneous ribonucleoprotein k and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma.
Thymidine phosphorylase mRNA stability and protein levels are increased through ERK-mediated cytoplasmic accumulation of hnRNP K in nasopharyngeal carcinoma cells.
Neoplasm Metastasis
5-Fluorouracil-related gene expression in primary sites and hepatic metastases of colorectal carcinomas.
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs.
Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.
Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma.
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer.
Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer.
Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases.
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer.
Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma.
Clinical significance of pyrimidine nucleoside phosphorylase in colorectal carcinoma.
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.
Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma.
Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma.
Correlation between expression levels of thymidine phosphorylase (dThdPase) and clinical features in human gastric carcinoma.
Correlation between tumor angiogenesis and expression of thymidine phosphorylase, and patient outcome in uterine cervical carcinoma.
Correlation of thymidine phosphorylase staining and the Ki-67 labeling index to clinicopathologic factors and hepatic metastasis in patients with colorectal cancer.
Effects of Platelet-Derived Endothelial Cell Growth Factor and Doppler Perfusion Index in Patients with Colorectal Hepatic Metastases.
Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
Expression of angiogenic factors and tumor progression in human neuroblastoma.
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers.
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.
Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma.
Expression of platelet-derived endothelial cell growth factor in bladder carcinoma.
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions.
Expression of pyrimidine nucleoside phosphorylase mRNA plays an important role in the prognosis of patients with oesophageal cancer.
Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics.
Expression of thymidine phosphorylase in human gastric carcinoma.
Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas.
Fatty liver suppressed the angiogenesis in liver metastatic lesions.
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives.
Heterogeneity and clinical role of thymidine phosphorylase activity in gastric cancer.
High level concentration of pyrimidine nucleoside phosphorylase in esophageal squamous cell carcinoma but no correlation with clinicopathological parameters.
Highly aggressive behavior and poor prognosis of small cell carcinoma in the stomach: flow cytometric and immunohistochemical analysis.
Histochemical study of angiogenesis in basaloid squamous carcinoma of the esophagus.
Immunohistochemical demonstration of angiogenic growth factors and EGF receptor in hepatic metastases and primary human gastric cancer.
Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose.
Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration.
Occurrence of hematogenous metastasis and serum levels of thymidine phosphorylase in colorectal cancer.
Papers to appear in forthcoming issues
PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis.
Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells.
Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer.
Platelet-derived endothelial cell growth factor mediates Rho-associated coiled-coil domain kinase messenger RNA expression and promotes cell motility.
Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer.
Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy.
Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma.
Prognostic significance of the serum thymidine phosphorylase levels in venous blood drainage specimens in patients with colorectal cancer.
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue.
Reliability of platelet-derived endothelial cell growth factor as a prognostic factor for oral and oropharyngeal carcinomas.
Research development of the relationship between thymidine phosphorylase expression and colorectal carcinoma.
Role of angiogenesis in the development and growth of liver metastasis.
Role of lymphangiogenesis in epithelial ovarian cancer.
Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma.
Specific enhanced expression of platelet-derived endothelial cell growth factor in submucosa of human colorectal cancer.
Suppression of metastasis by thymidine phosphorylase inhibitor.
Synthesis and evaluation of multisubstrate bicyclic pyrimidine nucleoside inhibitors of human thymidine phosphorylase.
Synthesis of 6-aminouracils and pyrrolo[2,3-d]pyrimidine-2,4-diones and their inhibitory effect on thymidine phosphorylase.
Synthesis of pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors of thymidine phosphorylase.
TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma.
The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion.
The influence of pyrimidine nucleoside phosphorylase activity on metastasis of breast cancer.
The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus.
The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Thymidine phosphorylase activates NF?B and stimulates the expression of angiogenic and metastatic factors in human cancer cells.
Thymidine phosphorylase expression in gastric carcinoma as a marker for metastasis.
Thymidine phosphorylase inhibitors: recent developments and potential therapeutic applications.
Thymidine phosphorylase promotes metastasis and serves as a marker of poor prognosis in hepatocellular carcinoma.
Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma.
Thymidine phosphorylase/platelet-derived endothelial cell growth factor is upregulated in advanced solid types of gastric cancer.
Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis.
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum.
Tumor angiogenesis as an independent prognostic factor after extended radical esophagectomy for invasive squamous cell carcinoma of the esophagus.
Tumor growth pattern and thymidine phosphorylase expression are related with the risk of hematogenous metastasis in patients with Astler Coller B1/B2 colorectal carcinoma.
Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination.
Up-regulated pyrimidine nucleoside phosphorylase in breast carcinoma correlates with lymph node metastasis.
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors.
[Clinicopathological significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced colorectal cancer]
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase) and clinicopathological factors in patients with gastric cancer]
[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]
[Immunohistochemical staining of thymidine phosphorylase in primary colorectal carcinoma and metastases]
[Long-term outcome of preoperative chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR) for gastric cancer]
[Malignancy of gastric cancer analyzed by the expression of thymidine phosphorylase]
[PyNPase activity in primary and metastatic colorectal cancer]
[Successful treatment of hepatic metastasis of gastric cancer with 5'-DFUR and Lentinan]
[The expression of platelet-derived endothelial cell growth factor in liver cancer]
[Thymidine phosphorylase expression in hepatic metastasis from colorectal carcinoma]
Neoplasm, Residual
Prognostic significance of ultrasound derived intratumoral peak systolic velocity in epithelial ovarian cancer.
Thymidine phosphorylase in human esophageal squamous cell carcinoma.
Neoplasms
"Stromatogenesis" and tumor progression.
2-Arylquinazolin-4(3H)-ones: A novel class of thymidine phosphorylase inhibitors.
2-Deoxy-D-ribose, a downstream mediator of thymidine phosphorylase, regulates tumor angiogenesis and progression.
3'-Deoxy-3'-[
4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression.
5-Nitrouracil stabilizes the plasma concentration values of 5-FU in colorectal cancer patients receiving capecitabine.
A case of metastatic breast cancer achieving complete response by combination therapy with 5'-deoxy-5-fluorouridine and cyclophosphamide.
A case report of papilla Vater carcinoma showing positive expression of thymidine phosphorylase.
A comparative study of the antitumor activities of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine (Ro09-1390) on human digestive organ cancer xenograft lines transplanted into nude mice.
A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa.
A kinetic, modeling and mechanistic re-analysis of thymidine phosphorylase and some related enzymes.
A novel glial growth inhibitory factor, gliostatin, derived from neurofibroma.
A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.
A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients.
A prospective randomized trial comparing capecitabine-based chemoradiotherapy with 5-FU-based chemoradiotherapy in neoadjuvant setting in locally advanced carcinoma rectum.
A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.
A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer.
A role of thymidine phosphorylase and P53 tissue protein expression in biology of endometrial cancer.
A similarity model for the human angiogenic factor, thymidine phosphorylase/platelet derived-endothelial cell growth factor.
Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells.
Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors.
Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines.
Activity of thymidilate "salvage pathway" enzymes in human gastric cancer and blood serum: correlation with treatment modalities.
Advanced gastric cancer with peritoneal dissemination successfully treated with paclitaxel and doxifluridine: a case report.
Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs.
An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed.
Angiogenesis and endometrial cancer.
Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast.
Angiogenesis and lymphangiogenesis of gastric cancer.
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer.
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in endometrial cancer.
Angiogenesis in gastric cancer: importance of the thymidine phosphorylase expression of cancer cells as an angiogenic factor.
Angiogenesis in metastatic verrucous carcinoma of the uterine cervix.
Angiogenesis in ovarian clear cell carcinoma and its relation to endometriosis.
Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
Angiogenesis-related factors are molecular targets for diagnosis and treatment of patients with esophageal carcinoma.
Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas.
Angiogenic effect of naive and 5-fluorouracil resistant colon carcinoma on endothelial cells in vitro.
Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer.
Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.
Angiogenic factors stimulate mast-cell migration.
Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling.
Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells.
Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Anti-tumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis.
Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap.
Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice.
Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways.
Antimalarial drug pyrimethamine plays a dual role in anti-tumor proliferation and metastasis through targeting DHFR and TP.
Antitumor activity of 5'-deoxy-5-fluorouridine in human digestive organ cancer xenografts and pyrimidine nucleoside phosphorylase activity in normal and neoplastic tissues from human digestive organs.
Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor.
Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
Association of thymidine phosphorylase concentration with ultrasound-derived indices of blood flow in ovarian masses.
Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma.
Augmentation of antitumor activity of 5'-deoxy-5-fluorouridine by thymosin fraction 5 in mouse bladder cancer cells in vitro and in vivo.
Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.
Biological role of thymidine phosphorylase in human astrocytic tumors.
Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells.
Cancer-Stromal Cell Interaction and Tumor Angiogenesis in Gastric Cancer.
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Capecitabine (Xeloda): from the laboratory to the patient's home.
Capecitabine and radiation therapy for advanced gastrointestinal malignancies.
Capecitabine bioequivalence in healthy volunteers.
Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.
Capecitabine in carcinoma of the pancreas.
Capecitabine induced cardiotoxicity: a case report and review of literature.
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Capecitabine.
Capecitabine: a novel agent for the treatment of solid tumors.
Capecitabine: preclinical pharmacology studies.
Changes in thymidine phosphorylase gene expression related to treatment of rectal cancer.
Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts.
Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients.
Clinical impact of thymidine phosphorylase expression in gastric cancer.
Clinical implication of expression of platelet-derived endothelial cell growth factor (PD-ECGF) in metastatic lesions of uterine cervical cancers.
Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers.
Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers.
Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer.
Clinical significance of pyrimidine nucleoside phosphorylase in colorectal carcinoma.
Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas.
Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer.
Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.
Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma.
Co-expression of thymidine phosphorylase and heme oxygenase-1 in macrophages in human malignant vertical growth melanomas.
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.
Combination effect of an angiogenesis inhibitor agm-1470 with 5'-deoxy-5-fluorouridine, and with hormonal drugs in dmba-induced rat mammary-tumors.
Combination of oral fluoropyrimidine and docetaxel: reappraisal of synergistic effect against gastric carcinoma xenografts.
Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma.
Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue.
Comparative antitumor activity and intestinal toxicity of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine.
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Comparison of the pyrimidine nucleoside phosphorylase activity in human tumors and normal tissues.
Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.
Concurrent expression of angiogenic growth factors and neovascularization during tumourigenesis in colorectal carcinoma patients.
Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.
Correlation between elevated intratumoral thymidine phosphorylase and prognosis of node-positive breast carcinoma undergoing adjuvant doxifluridine treatment.
Correlation between expression levels of thymidine phosphorylase (dThdPase) and clinical features in human gastric carcinoma.
Correlation between expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) and microvessel density in early-stage human colon carcinomas.
Correlation between malignancy grade and p53 gene in relation to thymidine phosphorylase activity in colorectal cancer patients.
Correlation between spontaneous apoptosis and the expression of angiogenic factors in advanced gastric adenocarcinoma.
Correlation between thymidine phosphorylase expression and invasion phenotype in cervical carcinoma cells.
Correlation between tumor angiogenesis and expression of thymidine phosphorylase, and patient outcome in uterine cervical carcinoma.
Correlation of thymidine phosphorylase staining and the Ki-67 labeling index to clinicopathologic factors and hepatic metastasis in patients with colorectal cancer.
Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Crystal structure of human thymidine phosphorylase in complex with a small molecule inhibitor.
Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase.
Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine.
Cytotoxic response of 5-fluorouracil-resistant cells to gene- and cell-directed enzyme/prodrug treatment.
Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
Demethoxycurcumin sensitizes the response of non-small cell lung cancer to cisplatin through downregulation of TP and ERCC1-related pathways.
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in vitro Toxicity, and Impact on Human Glioblastoma Cancer.
Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines.
Development and characterization of 1C6-203, a new monoclonal antibody specific to human thymidine phosphorylase.
Development of inhibitors of pyrimidine metabolism.
Differences and relationships of thymidine phosphorylase expression in tumor-associated macrophages and cancer cells in squamous cell carcinoma of the esophagus.
Different angiogenic pathways characterize superficial and invasive bladder cancer.
Different angiogenic pathways in human cervical cancers.
Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival.
Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase.
Distinct substrate specificity and physicochemical characterization of native human hepatic thymidine phosphorylase.
Distribution of thymidine phosphorylase activity in gastric carcinoma and adjacent normal gastric tissue.
DNA synthesis inhibitors for the treatment of gastrointestinal cancer.
Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo.
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
Effect of a combined administration of 5-fluorouracil and medroxyprogesterone acetate on pyrimidine nucleoside phosphorylases and thymidylate synthetase in 7,12-dimethylbenz.
Effect of administration of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on the anti-tumor efficacy of 5-fluoro-2'-deoxyuridine against murine colon tumor C26-10.
Effect of intratumoral OK-432 administration of thymidine phosphorylase expression in human gastric carcinoma.
Effects of 5'-DFUR and lentinan on cytokines and PyNPase against AH66 ascites hepatoma in rats.
Effects of 5'-DFUR and OK-432 on cytokines and thymidine phosphorylase in tumor tissue of gastric cancer patients.
Effects of introduction of dThdPase cDNA on sensitivity to 5'-deoxy-5-fluorouridine and tumor angiogenesis.
Effects of platelet-derived endothelial cell growth factor/thymidine phosphorylase, substrate, and products in a three-dimensional model of angiogenesis.
Effects of sex steroids and growth factors on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in ovarian adenocarcinoma OMC-3 cells.
Effects of thymidine phosphorylase levels in cancer, background mucosa, and regional lymph nodes on survival of advanced gastric cancer patients receiving postoperative fluoropyrimidine therapy.
Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
Endogenous gamma-interferon activates thymidine phosphorylase in colorectal cancer tissue.
Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma.
Enhanced Anticancer Activity of 5'-DFUR-PCL-MPEG Polymeric Prodrug Micelles Encapsulating Chemotherapeutic Drugs.
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.
Enhancement of 5-fluoro-2'-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside.
Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study.
Enhancement of antitumor activity of 5'-deoxy-5-fluorouridine (Furtulon) by taxane in human gastric cancer xenografts.
Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA.
Enhancement of Mitomycin C-Induced Cytotoxicity by Curcumin Results from Down-Regulation of MKK1/2-ERK1/2-Mediated Thymidine Phosphorylase Expression.
Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues.
Ets-1 expression in vascular endothelial cells as an angiogenic and prognostic factor in colorectal carcinoma.
Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.
Evaluation of tumor angiogenesis and thymidine phosphorylase tissue expression in patients with endometrial cancer.
Evaluation of [(18)F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer.
Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer.
Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy.
Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma.
Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma.
Expression of angiogenic growth factors in paragangliomas.
Expression of basic fibroblast growth factor is associated with a good outcome in patients with squamous cell carcinoma of the esophagus.
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers.
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.
Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma.
Expression of platelet-derived endothelial cell growth factor in bladder carcinoma.
Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease.
Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors.
Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma.
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in cervical intraepithelial neoplasia.
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human bladder cancer.
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions.
Expression of pyrimidine nucleoside phosphorylase (PyNPase) in colorectal cancer.
Expression of pyrimidine nucleoside phosphorylase mRNA plays an important role in the prognosis of patients with oesophageal cancer.
Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations.
Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors.
Expression of the angiogenic factor thymidine phosphorylase in THP-1 monocytes: induction by autocrine tumor necrosis factor-alpha and inhibition by aspirin.
Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques: In vivo correlation of lesional microvessel density and constrictive vascular remodeling.
Expression of the thymidine phosphorylase gene in epithelial ovarian cancer.
Expression of thymidine phosphorylase and angiogenesis in human ovarian tumor.
Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics.
Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor.
Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder.
Expression of thymidine phosphorylase by macrophages in colorectal cancer tissues.
Expression of thymidine phosphorylase in choroidal malignant melanoma associated with neovascular glaucoma.
Expression of thymidine phosphorylase in epithelial ovarian cancer: correlation with angiogenesis, apoptosis, and ultrasound-derived peak systolic velocity.
Expression of thymidine phosphorylase in human cervical cancer.
Expression of thymidine phosphorylase in human gastric carcinoma.
Expression of thymidine phosphorylase in human superficial bladder cancer.
Expression of thymidine phosphorylase in lymph nodes involved with mycosis fungoides and sézary syndrome.
Expression of thymidine phosphorylase in malignant ovarian tumors: correlation with microvessel density and an ultrasound-derived index of angiogenesis.
Expression of thymidine phosphorylase in uterine sarcoma and uterine leiomyoma: association with microvessel density and Doppler blood flow analysis.
Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas.
Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: implication for method to detect expression of these molecules in clinic.
Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis.
Expression of uridine and thymidine phosphorylase genes in human breast carcinoma.
Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease.
Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer.
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.
Fluorescence and computational studies of thymidine phosphorylase affinity toward lipidated 5-FU derivatives.
Fluorescent molecular rotors as sensors for the detection of thymidine phosphorylase.
Frequent expression of thymidine phosphorylase in Epstein-Barr virus-associated gastric carcinoma of diffuse type.
Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil.
Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer.
Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study.
H pylori status and angiogenesis factors in human gastric carcinoma.
Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma.
HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer.
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives.
Heterogeneity and clinical role of thymidine phosphorylase activity in gastric cancer.
High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancers.
High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection.
High level concentration of pyrimidine nucleoside phosphorylase in esophageal squamous cell carcinoma but no correlation with clinicopathological parameters.
Highly aggressive behavior and poor prognosis of small cell carcinoma in the stomach: flow cytometric and immunohistochemical analysis.
Histochemical study of angiogenesis in basaloid squamous carcinoma of the esophagus.
Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer.
Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins.
Identification and comparative analysis of thymidine phosphorylase in the plasma of healthy subjects and cancer patients.
Identification of 1,2,4-triazoles as new thymidine phosphorylase inhibitors: Future anti-tumor drugs.
Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening.
Identification of aspartic acid-203 in human thymidine phosphorylase as an important residue for both catalysis and non-competitive inhibition by the small molecule "crystallization chaperone" 5'-O-tritylinosine (KIN59).
IFN gamma-induced up-regulation of PD-ECGF/TP enhances the cytotoxicity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in bladder cancer cells.
Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.
Immunohistochemical demonstration of angiogenic growth factors and EGF receptor in hepatic metastases and primary human gastric cancer.
Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors.
Immunohistochemical expression of thymidine phosphorylase in human endometrial cancer.
Immunohistochemical localization of platelet-derived endothelial cell growth factor expression and its relation to angiogenesis in prostate.
Immunohistochemical localization of thymidine phosphorylase in gastric cancer: is there a role of the differential expression in tumor cells and associated stromal cells?
Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer.
Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis.
Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma.
Improving chemoradiotherapy in rectal cancer.
In silico binding analysis and SAR elucidations of newly designed benzopyrazine analogs as potent inhibitors of thymidine phosphorylase.
In vitro and in vivo evaluations of a radioiodinated thymidine phosphorylase inhibitor as a tumor diagnostic agent for angiogenic enzyme imaging.
Increased expression of platelet-derived endothelial cell growth factor in human hepatocellular carcinomas correlated with high Edmondson grades and portal vein tumor thrombosis.
Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue.
Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response.
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.
Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.
Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity.
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Induction of thymidine phosphorylase expression by AZT contributes to enhancement of 5'-DFUR cytotoxicity.
Infiltration of thymidine phosphorylase-positive macrophages is closely associated with tumor angiogenesis and survival in intestinal type gastric cancer.
Influence of platelet-derived endothelial cell growth factor/thymidine phosphorylase on the cell cycle in head and neck squamous cell carcinoma in vitro.
Inhibition of 5'-deoxy-5-fluorouridine phosphorolysis by acyclothymidine in tumor cell homogenates.
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda(®).
Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose.
Integrating oxaliplatin into the management of colorectal cancer.
Interferon- ? Enhances 5'-Deoxy-5-Fluorouridine-Induced Apoptosis by ERK-Dependant Upregulation of Thymidine Phosphorylase.
Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells.
Interrelationship of platelet-derived endothelial cell growth factor, liver macrophages, and tumor microvessel density in patients with cholangiocellular carcinoma.
Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer.
Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis.
Lembehsterols A and B, novel sulfated sterols inhibiting thymidine phosphorylase, from the marine sponge Petrosia strongylata.
Localization of thymidine phosphorylase in advanced gastric and colorectal cancer.
Localization of thymidine phosphorylase in breast cancer tissue.
Logistic regression model of the clinical response to 5-fluorouracil based chemotherapy for metastatic colorectal cancer patients.
Long-term effect of gene therapy for chronic ischemic myocardium using platelet-derived endothelial cell growth factor in dogs.
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer.
Macrophage infiltration-associated thymidine phosphorylase expression correlates with increased microvessel density and poor prognosis in astrocytic tumors.
Making Capecitabine Targeted Therapy for Breast Cancer: Which is the Role of Thymidine Phosphorylase?
Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration.
Metformin Induces Cytotoxicity by Down-Regulating Thymidine Phosphorylase and Excision Repair Cross-Complementation 1 Expression in Non-Small Cell Lung Cancer Cells.
Microdissection is essential for gene expression analysis of irradiated rectal cancer tissues.
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.
Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.
Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer.
Molecular approach to breast cancer treatment.
Molecular basis for the involvement of thymidine phosphorylase in cancer invasion.
Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis.
Moving forward with capecitabine: a glimpse of the future.
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Multicomponent Coculture System of Cancer Cells and Two Types of Stromal Cells for In Vitro Evaluation of Anticancer Drugs.
Myocardial expression of PDECGF is associated with extracellular matrix remodeling in experimental myocardial infarction in rats.
Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation.
No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix.
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.
Novel (E)-5-(2-iodovinyl)-2'-deoxyuridine derivatives as potential cytostatic agents against herpes simplex virus thymidine kinase gene transfected tumors.
Novel prophylactic effect of doxifluridine in superficial bladder cancer.
Occurrence of hematogenous metastasis and serum levels of thymidine phosphorylase in colorectal cancer.
Orotate phosphoribosyltransferase localizes to the Golgi complex and its expression levels affect the sensitivity to anti-cancer drug 5-fluorouracil.
Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo.
Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis.
Oxidative stress and tumor progression in colorectal cancer.
Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation?
Papers to Appear in Forthcoming Issues
Papers to appear in forthcoming issues
Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy.
Perillyl alcohol as a protective modulator against rat hepatocarcinogenesis via amelioration of oxidative damage and cell proliferation.
Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
Pharmacology and clinical status of capecitabine.
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.
Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis.
Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver.
Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer.
Platelet-derived endothelial cell growth factor as a prognostic factor for radiotherapy outcome in patients with adenocarcinoma of the uterine cervix.
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.
Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer.
Platelet-derived endothelial cell growth factor expression is an independent prognostic factor in colorectal cancer patients after curative surgery.
Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells.
Platelet-derived endothelial cell growth factor inhibits DNA synthesis in vascular smooth muscle cells.
Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer.
Platelet-derived endothelial cell growth factor mediates Rho-associated coiled-coil domain kinase messenger RNA expression and promotes cell motility.
Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer.
Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase immunohistochemical expression in lymphoid tissue and lymphoid malignancies.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase inhibitor augments radiotherapeutic efficacy in experimental colorectal cancer.
Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.
Possible role of thymidine phosphorylase in gynecological tumors as an individualized treatment strategy.
Practical considerations in the use of oral fluoropyrimidines.
Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor.
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy.
Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma.
Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues.
Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase.
Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture.
Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients.
Prognostic role of angiogenesis and its correlations with thymidine phosphorylase and p53 expression in ductal adenocarcinoma of the pancreas.
Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer.
Prognostic significance of angiogenesis in human pancreatic cancer.
Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma.
Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma.
Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma.
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy.
Prognostic significance of ultrasound derived intratumoral peak systolic velocity in epithelial ovarian cancer.
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy.
Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress.
Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors.
PyNPase expression in human colon cancer.
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Pyrimidine nucleoside phosphorylase activity in tumour and matched normal gastrointestinal mucosa.
Pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase indicate chemosensitivity of human colon cancer specimens to doxifluridine and 5-fluorouracil, respectively.
Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer.
Pyrimidine nucleoside phosphorylase-activity and biological characteristics of breast-cancer.
Pyrimidine nucleosides in molecular PET imaging of tumor proliferation.
Pyrimidine nucleotide metabolism in human colon carcinomas: comparison of normal tissues, primary tumors and xenografts.
Radiation-induced thymidine phosphorylase upregulation in rectal cancer is mediated by tumor-associated macrophages by monocyte chemoattractant protein-1 from cancer cells.
Radiolabeled uracil derivative as a novel SPECT probe for thymidine phosphorylase: suppressed accumulation into tumor cells by target gene knockdown.
Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil.
Recent discovery of non-nucleobase thymidine phosphorylase inhibitors targeting cancer.
Regulation of cancer progression by inhibition of angiogenesis and induction of apoptosis.
Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells.
Regulation of the expression of the angiogenic enzyme platelet-derived endothelial cell growth factor/thymidine phosphorylase in endometrial isolates by ovarian steroids and cytokines.
Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer.
Relationship between biodistribution of a novel thymidine phosphorylase (TP) imaging probe and TP expression levels in normal mice.
Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines.
Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF.
Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39.
Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue.
Reliability of platelet-derived endothelial cell growth factor as a prognostic factor for oral and oropharyngeal carcinomas.
Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck.
Retroviral Vector-mediated Expression of Human Thyimidine Phosphorylase in Pancreatic Carcinoma Cells.
Role of angiogenesis in benign, premalignant and malignant vulvar lesions.
Role of angiogenesis in the development and growth of liver metastasis.
Role of lymphangiogenesis in epithelial ovarian cancer.
Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients.
Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion.
Role of thymidine phosphorylase in Fas-induced apoptosis.
Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma.
Role of tumor angiogenesis in gallbladder carcinoma: with special reference to thymidine phosphorylase.
Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen.
Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5'-deoxy-5-fluorouridine.
Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.
Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites.
Significance of expression of pyrimidine metabolizing genes in colon cancer.
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.
Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer.
Significance of thymidine phosphorylase expression in stromal cells around invasive front of rectal cancer.
Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma.
Significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor in carcinoma of the papilla of Vater.
Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma.
Specific enhanced expression of platelet-derived endothelial cell growth factor in submucosa of human colorectal cancer.
Stimulatory effects of EGF and TGF-alpha on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in uterine cervical-carcinoma SKG-IIIb cells.
Stromal angiogenesis in human glioma: a role of platelet-derived endothelial cell growth factor.
Studies on the designing of chemotherapy for gastric cancer in man, based on the tumor tissue concentration of anticancer agents.
Substrate specificity of a thymidine phosphorylase in human liver tumor.
Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells.
Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model.
Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity.
Suppression of tumor growth and downregulation of platelet-derived endothelial cell growth factor / thymidine phosphorylase in tumor cells by angiogenesis inhibitor TNP-470.
Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase.
Synthesis and evaluation of multisubstrate bicyclic pyrimidine nucleoside inhibitors of human thymidine phosphorylase.
Synthesis of 6-aminouracils and pyrrolo[2,3-d]pyrimidine-2,4-diones and their inhibitory effect on thymidine phosphorylase.
Synthesis of pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors of thymidine phosphorylase.
Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers.
Synthesis, evaluation of thymidine phosphorylase and angiogenic inhibitory potential of ciprofloxacin analogues: Repositioning of ciprofloxacin from antibiotic to future anticancer drugs.
Synthesis, molecular docking study and thymidine phosphorylase inhibitory activity of 3-formylcoumarin derivatives.
Synthesis, thymidine phosphorylase inhibition and molecular modeling studies of 1,3,4-oxadiazole-2-thione derivatives.
Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy.
Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts.
Tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and tumor xenografts.
The activities of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer depend on where the sample is taken.
The activity and expression of thymidine phosphorylase in human solid tumours.
The activity of thymidine phosphorylase as a new ovarian tumor marker.
The activity of thymidine phosphorylase correlates with tumor size and lymph nodes status in breast carcinoma.
The activity of thymidine phosphorylase in the uterine myomas and the myometrium in perimenopausal women.
The angiogenic factor thymidine phosphorylase up-regulates the cell adhesion molecule P-selectin in human vascular endothelial cells and is associated with P-selectin expression in breast cancers.
The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion.
The correlation of thymidine phosphorylase activity with the expression of interleukin 1 alpha, interferon alpha and interferon gamma in human colorectal carcinoma.
The cytosol activity of thymidine phosphorylase in endometrial cancer.
The degradation of 5'-deoxy-5-fluorouridine by pyrimidine nucleoside phosphorylase in normal and cancer tissues.
The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine.
The dual role of thymidine phosphorylase in cancer development and chemotherapy.
The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors.
The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
The efficacy of long-term oral chemotherapy with 5'-deoxy-5-fluorouridine and cyclophosphamide for recurrent breast cancer.
The evolution of fluoropyrimidine therapy: from intravenous to oral.
The evolving role of capecitabine in breast cancer.
The expression of platelet-derived endothelial cell growth factor in human bladder cancer.
The expression of thymidine phosphorylase and its correlation with angiogenesis in gastric adenocarcinoma.
The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas.
The Expression of Thymidine Phosphorylase in Cancer-infiltrating Inflammatory Cells in Stomach Cancer.
The expression of thymidine phosphorylase suppresses spontaneous apoptosis of cancer cells in esophageal squamous cell carcinoma.
The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery.
The influence of elevated levels of platelet-derived endothelial cell growth factor/thymidine phosphorylase on tumourigenicity, tumour growth, and oxygenation.
The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo.
The influence of pyrimidine nucleoside phosphorylase activity on metastasis of breast cancer.
The kinetic mechanism of Human Thymidine Phosphorylase - a molecular target for cancer drug development.
The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer.
The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites.
The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus.
The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas.
The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine.
The rational development of capecitabine from the laboratory to the clinic.
The relationship between clinicopathological factors and the reduction of pyrimidine nucleoside phosphorylase activity after preoperative administration of 5'-deoxy-5-fluorouridine.
The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer.
The role of peroxisome proliferator-activated receptor gamma in bladder cancer in relation to angiogenesis and progression.
The role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in tumor behavior.
The role of thymidine phosphorylase (TP) mRNA expression in angiogenesis of prostate cancer.
The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.
The role of thymidine phosphorylase expression in the invasiveness of gastric carcinoma.
The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells.
The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression.
The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers.
The significance of thymidine phosphorylase activity in hepatocellular carcinoma and chronic diseased livers: a special reference to liver fibrosis and multicentric tumor occurrence.
The significance of thymidine phosphorylase expression in colorectal cancer.
The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells.
The Thymidine Phosphorylase Imaging Agent 123I-IIMU Predicts the Efficacy of Capecitabine.
The use of capecitabine in the combined-modality therapy for rectal cancer.
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Three new acrylic acid derivatives from Achillea mellifolium as potential thymidine phosphorylase inhibitor: molecular docking and MD simulation studies.
Thymidine Catabolism as a Metabolic Strategy for Cancer Survival.
Thymidine catabolism promotes NADPH oxidase-derived reactive oxygen species (ROS) signalling in KB and yumoto cells.
Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Thymidine phoshorylase as a target for antiangiogenesis treatment.
Thymidine phoshorylase expression in breast cancer: the prognostic significance and its association with other angiogenesis related proteins and extracellular matrix components.
Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside.
Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma.
Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment.
Thymidine phosphorylase activates NF?B and stimulates the expression of angiogenic and metastatic factors in human cancer cells.
Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer.
Thymidine phosphorylase activity in plasma: a cancer marker or an artifact of ultrafiltration?
Thymidine phosphorylase activity in transitional cell cancer: relation to histological parameters and chemosensitivity to fluorouracil-related drugs.
Thymidine phosphorylase activity in tumor correlates with venous invasion.
Thymidine phosphorylase activity required for tumor angiogenesis and growth.
Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.
Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of t3 human colorectal carcinoma.
Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story.
Thymidine phosphorylase and prostrate cancer cell proliferation inhibitory activities of synthetic 4-hydroxybenzohydrazides: In vitro, kinetic, and in silico studies.
Thymidine phosphorylase as a target for imaging and therapy with thymine analogs.
Thymidine phosphorylase enhances reactive oxygen species generation and interleukin-8 expression in human cancer cells.
Thymidine Phosphorylase Expression and Microvascular Density Correlation Analysis in Canine Mammary Tumor: Possible Prognostic Factor in Breast Cancer.
Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer.
Thymidine phosphorylase expression causes both the increase of intratumoral microvessels and decrease of apoptosis in human esophageal carcinomas.
Thymidine phosphorylase expression correlates with tumor differentiation and Bcl-2 in invasive breast cancer.
Thymidine phosphorylase expression in endometrial carcinomas.
Thymidine phosphorylase expression in human colorectal mucosa, adenoma and carcinoma: role of p53 expression.
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis.
Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis.
Thymidine phosphorylase expression in tumor stroma of uterine cervical carcinomas: histological features and microvessel density.
Thymidine phosphorylase expression in tumor-infiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer.
Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas.
Thymidine phosphorylase expression is predominantly observed in stroma of well-differentiated adenocarcinoma of endometrium and correlates with a frequency of vascular involvement.
Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma.
Thymidine phosphorylase expression results in a decrease in apoptosis and increase in intratumoral microvessel density in human gastric carcinomas.
Thymidine phosphorylase in cancer aggressiveness and chemoresistance.
Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors.
Thymidine Phosphorylase in Cancer; Enemy or Friend?
Thymidine phosphorylase in human esophageal squamous cell carcinoma.
Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms.
Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.
Thymidine phosphorylase inhibitors: recent developments and potential therapeutic applications.
Thymidine phosphorylase is angiogenic and promotes tumor growth.
Thymidine phosphorylase is regulated by tamoxifen in T47D breast cancer cell line.
Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro.
Thymidine phosphorylase promotes angiogenesis and tumour growth in intrahepatic cholangiocarcinoma.
Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synoviocytes.
Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents.
Thymidine phosphorylase suppresses Fas-induced apoptotic signal transduction independent of its enzymatic activity.
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.
Thymidine phosphorylase/platelet-derived endothelial cell growth factor is upregulated in advanced solid types of gastric cancer.
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
Thymidylate synthase: a critical target in cancer therapy?
Tissue concentration of platelet-derived endothelial cell growth factor in colorectal cancer.
Tissue levels of pyrimidine nucleoside phosphorylase activity in human and rodent bladder cancer and normal bladder tissue.
Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro.
Transduction of thymidine phosphorylase cDNA facilitates efficacy of cytosine deaminase/5-FC gene therapy for malignant brain tumor.
Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma.
Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum.
Tumor angiogenesis as an independent prognostic factor after extended radical esophagectomy for invasive squamous cell carcinoma of the esophagus.
Tumor growth pattern and thymidine phosphorylase expression are related with the risk of hematogenous metastasis in patients with Astler Coller B1/B2 colorectal carcinoma.
Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.
Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas.
Tumor specific conversion of a pyrimidine antimetabolite.
Tumor vascularity predicts recurrence in differentiated thyroid carcinoma.
Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination.
Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality.
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C.
Validation of real-time reverse-transcription-polymerase chain reaction for quantification of capecitabine-metabolizing enzymes.
Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
Variations in the expression of platelet-derived endothelial cell growth factor in human colorectal polyps.
Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer.
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer.
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer.
Vascular endothelial growth factor and thymidine phosphorylase expression in salivary gland tumors with distinct metastatic behavior.
Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis.
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
Vascular endothelial growth factor.
Vision of the future: capecitabine.
What is the role of thymidine phosphorylase in tumor angiogenesis.
X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts.
Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors.
Xeloda in colorectal cancer.
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
[5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues]
[5-Fluorouracil level and pyrimidine nucleoside phosphorylase activity in cancer patients after oral administration of doxifluridine (5'-DFUR)]
[A case of gastric carcinoma treated effectively with 5'-DFUR]
[A change of tumor PyNPase level at intraperitoneal and intravenous administrations of paclitaxel]
[A new anticancer drug, 5'-deoxy-5-fluorouridine (5'-DFUR)]
[A study of preoperative administration of 5'-DFUR in patients with colo-rectal cancer]
[Activities of enzymes converting 5-fluorouracil to 5-fluorouridine-5' monophosphate and 5-fluorodeoxyuridine-5' monophosphate in subcultured cell lines and solid tumor tissues]
[Activities of pyrimidine nucleoside phosphorylase in brain tumors and antitumor effect of 5'-DFUR]
[Activity of the enzymes of DNA metabolism in the blood of patients with breast cancer]
[Age-dependent characteristics of metabolism of DNA precursors in healthy women, patients with mastopathy and breast cancer]
[Analyses of factors influencing the chemosensitivity of human tumors xenografted into nude mice (I)]
[Antitumor cytokines]
[Capecitabine: an oral chemotherapeutic agent against metastatic breast and colorectal cancer]
[Clinical effect of 5'-deoxy-5-fluorouridine (5'-DFUR)]
[Clinical efficacy of low-dose weekly docetaxel combined with oral 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced or metastatic breast cancer: a pilot trial]
[Clinical significance of pyrimidine nucleoside phosphorylase (PyNPase) in breast cancer]
[Clinicopathological significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced colorectal cancer]
[Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
[Conversion of 5'-deoxy-5-fluorouridine to 5-FU by pyrimidine nucleoside phosphorylases in normal and tumor tissues from rodents bearing tumors and cancer patients]
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase) and clinicopathological factors in patients with gastric cancer]
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase)/platelet-derived endothelial cell growth factor and histological prognostic factor, and influences of 5'-deoxy-5-fluorouridine (5'-DFUR) administration on PyNPase levels. 5'-DFUR Joint Research Group in the Osaka Area for Gastric Cancer]
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase)/thymidine phosphorylase/platelet-derived endothelial cell growth factor and histological prognostic factor, and influence of 5'-deoxy-5-fluorouridine (5'-DFUR) administration on PyNPase activities and serum immunosuppressive acidic protein levels. A study group of oral anti-cancer drugs in Seiban/Tajima area]
[Determination of thymidine phosphorylase in adenoma and cancer of the human prostate]
[Discovery and development of novel anticancer drug capecitabine]
[Distributions of pyrimidine nucleoside phosphorylase (PyNPase) in tissues of benign and malignant mammary diseases--immunohistochemical observations]
[Effect of 5'-deoxy-5-fluorouridine (5'-DFUR) on the activity of pyrimidine nucleoside phosphorylase (pyNPase) in normal and tumor tissues of human stomach]
[Effect of preoperative oral 5'-DFUR on PyNPase level in gastrointestinal malignant tumor tissues]
[Effect on 5'-deoxy-5-fluorouridine (5'-DFUR) of pyrimidine nucleoside phosphorylase (PyNPase), matrix metalloprotease and serum IAP values. Hokuriku Colorectal Cancer Chemotherapy Study Group]
[Enzymatic conversion of tegafur in human tumor tissue]
[Evaluation by multiple regression analysis of factors influencing the chemosensitivity of human tumors xenografted into nude mice]
[Expression of thymidine phosphorylase in cancer]
[Expression of thymidine phosphorylase in primary colorectal cancer and liver metastasis-relationship between mRNA levels in cancer cells and protein levels in cancerous tissue]
[Expression rates of three angiogenic factors in hepatocellular carcinoma and their relation with microvessel density and portal vein tumor thrombosis]
[Immunohistochemical staining of thymidine phosphorylase in primary colorectal carcinoma and metastases]
[Immunohistochemical study of thymidine phosphorylase in uterine cervical intraepithelial neoplasia]
[In vivo study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) in meningeal dissemination of malignant tumor]
[Influence of intratumor administration of OK-432 on the tumor selectivity of 5'-DFUR]
[Influence of the selected pyrimidine compounds on the activity of thymidine phosphorylase from normal and tumor endometrial cells]
[Influence of the thymidine phosphorylase (platelet-derived endothelial cell growth factor) on tumor angiogenesis. Catalytic activity of enzyme inhibitors]
[Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts]
[Influences of 5'-deoxy-5-fluorouridine (5'-DFUR) on cell cycle in patients with breast cancer]
[Ki-67 expression, thymidine phosphorylase and PTEN in intraepithelial cervical carcinoma].
[Lactate dehydrogenase, adenosine deaminase and thymidine phosphorylase activity of blood and tissues in breast tumor patients]
[Localization of platelet-derived endothelial cell growth factor in human glioblastoma and meningioma]
[Malignancy of gastric cancer analyzed by the expression of thymidine phosphorylase]
[Measurement of 5'-deoxy-5-fluorouridine (5'-DFUR) by high-performance liquid chromatography and studies on pharmacokinetics of 5'-DFUR and 5-fluorouracil by oral and intravenous administration]
[Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine]
[Mode of action of fluoropyrimidines, in relation to their clinical application]
[Molecular markers as basis for chemotherapy?]
[New molecular target of cancer therapy--angiogenesis regulator VEGF]
[Phase I clinical trial evaluation of capecitabine in concurrent combination of radiotherapy in nasopharyngeal carcinoma]
[Prognostic effect of PyNPase (pyrimidine nucleoside phosphorylase) activity in breast cancer]
[PyNPase activity in primary and metastatic colorectal cancer]
[PyNPase and DPD expression potentially predict response to 5'-DFUR treatment for node-positive breast cancer patients]
[PyNPase expression and cancer progression in the colorectum]
[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]
[Significance of 5'-deoxy-5-fluorouridine (5'-DFUR) administration before surgery for advanced gastric and colonic cancers--activity of pyrimidine nucleoside phosphorylase (PyNPase) and serum immunosuppressive acidic protein (IAP)]
[Significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced gastric cancers]
[Significance of pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase levels to predict postoperative recurrence in primary breast cancer]
[Significance of tissue PyNPase, TS, and DPD activities in breast cancer]
[Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration]
[Study of PyNPase activity in patients with gastric cancer--the association with preoperative IAP values]
[Study on pyrimidine nucleoside phosphorylase (PyNPase) activity in resected tissues of patients with gastric cancer]
[Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer]
[Successful treatment of hepatic metastasis of gastric cancer with 5'-DFUR and Lentinan]
[The alteration of PyNPase activity in breast cancers due to preoperative oral administration of 5'-DFUR]
[The analysis of thymidine phosphorylase examined by ELISA in bladder cancer]
[The efficacy of combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR), cyclophosphamide (CPA) and medroxyprogesterone acetate (MPA) for bone metastasis in breast cancer patients]
[The enzymatic activity of DNA metabolism of the blood in patients operated on in stomach cancer]
[The importance of tumor angiogenesis as a prognostic indicator in primary breast cancer]
[The mRNA expression of platelet-derived endothelial cell growth factor of bladder transitional cell carcinoma and its relation to invasiveness]
[The relation between pyrimidine nucleoside phosphorylase (PyNPase) activity in colorectal cancer tissues and pathological effects]
[The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].
[The significance of platelet-derived endothelial cell growth factor mRNA expression in superficial bladder cancer]
[The thymidine phosphorylase as the platelet-derived endothelial cell growth factor of endometrial cancer]
[Thymidine phosphorylase activity and neo-angiogenesis in ovarian cancer]
[Thymidine phosphorylase as a prognostic factors of breast cancers]
[Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]
[Use of enzyme test in chemotherapy of patients with cancer of the breast]
Neoplasms, Squamous Cell
Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma.
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Nephrosis
Experimentally induced puromycine aminonucleoside nephrosis (PAN) in rats: evaluation of angiogenic protein platelet-derived endothelial cell growth factor (PD-ECGF) expression in glomeruli.
Neuroblastoma
Correlations of dihydropyrimidine dehydrogenase, thymidine phosphorylase and thymidine kinase activities in strongly and weakly malignant cultured murine neuroblastoma cells.
[Antitumor cytokines]
Neurodegenerative Diseases
Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B.
Neurofibroma
A novel glial growth inhibitory factor, gliostatin, derived from neurofibroma.
Neurologic Manifestations
Pregnancy in MNGIE: a clinical and metabolic honeymoon.
Odontogenic Tumors
Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors.
Ophthalmoplegia
Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE).
Inherited peripheral neuropathies due to mitochondrial disorders.
Leukoencephalopathy in Mitochondrial Neurogastrointestinal Encephalomyopathy-Like Syndrome with Polymerase-Gamma Mutations.
Mitochondrial neurogastrointestinal encephalomyopathy associated with progressive hearing loss.
Pitfalls in diagnosing mitochondrial neurogastrointestinal encephalomyopathy.
Transient clinical improvement of a mitochondrial neurogastrointestinal encephalomyopathy-like syndrome after allogeneic haematopoietic stem cell transplantation.
[Peripheral neuropathies due to mitochondrial disorders]
Oropharyngeal Neoplasms
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients.
Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer.
Ovarian Neoplasms
4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression.
Could serologic and ultrasonographic indexes be useful for therapeutic decisions in patients with ovarian cancer?
Effects of platelet-derived endothelial cell growth factor/thymidine phosphorylase, substrate, and products in a three-dimensional model of angiogenesis.
Expression of angiogenesis factors in monolayer culture, multicellular spheroid and in vivo transplanted tumor by human ovarian cancer cell lines.
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in ovarian cancers.
Expression of thymidine phosphorylase in malignant ovarian tumors: correlation with microvessel density and an ultrasound-derived index of angiogenesis.
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Role of lymphangiogenesis in epithelial ovarian cancer.
The activity of thymidine phosphorylase as a new ovarian tumor marker.
Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer.
Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.
[Investigation of 5-fluorouracil (5-FU) levels and pyrimidine nucleoside phosphorylase activities in the tissues from patients with uterine cervical and ovarian cancers after oral administration of 5'-DFUR]
[Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer]
[Thymidine phosphorylase activity and neo-angiogenesis in ovarian cancer]
Paget's Disease, Mammary
The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget's disease of the vulva and breast.
Pancreatic Neoplasms
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis.
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
Prognosis Relevance of Serum Cytokines in Pancreatic Cancer.
Prognostic significance of angiogenesis in human pancreatic cancer.
Prognostic value of thymidine phosphorylase expression for pancreatic cancer.
Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.
[The thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio in pancreatic cancer]
Pancreatitis, Chronic
Mitochondrial DNA A3243G mutation involved in familial diabetes, chronic intestinal pseudo-obstruction and recurrent pancreatitis.
Paraganglioma
Expression of angiogenic growth factors in paragangliomas.
Peripheral Arterial Disease
Platelet-derived endothelial cell growth factor gene therapy for limb ischemia.
Peripheral Nervous System Diseases
Late-onset MNGIE without peripheral neuropathy due to incomplete loss of thymidine phosphorylase activity.
Leukoencephalopathy in Mitochondrial Neurogastrointestinal Encephalomyopathy-Like Syndrome with Polymerase-Gamma Mutations.
Mitochondrial neurogastrointestinal encephalomyopathy associated with progressive hearing loss.
POG01 Anti-thymidine phosphorylase antibodies in the diagnosis of mitochondrial neurogastrointestinal encephalomyopathy.
Peripheral Vascular Diseases
Platelet-derived endothelial cell growth factor gene therapy for limb ischemia.
Phenylketonurias
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
Phyllodes Tumor
[Distributions of pyrimidine nucleoside phosphorylase (PyNPase) in tissues of benign and malignant mammary diseases--immunohistochemical observations]
Plague
[Thymidine phosphorylase activity and its relationship to trimethoprim in initial strains and thymidine-, thymine-dependent and trimethoprim-resistant mutants of plague microbe]
Polyneuropathies
Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE).
Poroma
Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Purine and pyrimidine activities in acute and chronic lymphocytic leukaemia: relation to cellular proliferative status.
Prostatic Neoplasms
Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells.
Expression of thymidine phosphorylase correlates with microvessel density in prostate cancer.
Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer.
Immunohistochemical localization of platelet-derived endothelial cell growth factor expression and its relation to angiogenesis in prostate.
The role of thymidine phosphorylase (TP) mRNA expression in angiogenesis of prostate cancer.
[Determination of thymidine phosphorylase in adenoma and cancer of the human prostate]
Pseudolymphoma
Pyrimidine and purine activities in non-Hodgkin's lymphoma. Correlation with histological status and survival.
Psoriasis
2-Arylquinazolin-4(3H)-ones: A novel class of thymidine phosphorylase inhibitors.
Synthesis, molecular docking study and thymidine phosphorylase inhibitory activity of 3-formylcoumarin derivatives.
Pyloric Stenosis, Hypertrophic
Study of insulin-like growth factor-1 (IGF-1) and platelet-derived endothelial cell growth factor (PDEGF) expression in children with infantile hypertrophic pyloric stenosis.
Rectal Neoplasms
Changes in thymidine phosphorylase gene expression related to treatment of rectal cancer.
Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.
Immunohistochemical Markers as Predictors of Histopathologic Response and Prognosis in Rectal Cancer Treated with Preoperative Adjuvant Therapy: State of the Art.
Importance of thymidine phosphorylase expression at the invasive front of T3 rectal cancer as a prognostic factor.
Importance of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase expression at the invasive front of T3 rectal cancer as prognostic factors.
Preoperative Chemoradiation for Rectal Cancer Using Capecitabine and Celecoxib Correlated with Posttreatment Assessment of Thymidylate Synthase and Thymidine Phosphorylase Expression.
Pretreatment Expression of 13 Molecular Markers as a Predictor of Tumor Responses After Neoadjuvant Chemoradiation in Rectal Cancer.
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
Radiation-induced thymidine phosphorylase upregulation in rectal cancer is mediated by tumor-associated macrophages by monocyte chemoattractant protein-1 from cancer cells.
Significance of thymidine phosphorylase expression in stromal cells around invasive front of rectal cancer.
The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery.
Thymidine phosphorylase and hypoxia-inducible factor 1-? expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C.
Rhinitis, Allergic
Expression of platelet-derived endothelial cell growth factor and vascularity in the nasal mucosa from allergic rhinitis.
The role of thymidine phosphorylase in the pathogenesis of allergic rhinitis.
Sarcoma
Expression of thymidine phosphorylase in uterine sarcoma and uterine leiomyoma: association with microvessel density and Doppler blood flow analysis.
[Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]
Sarcoma 180
[Activities of pyrimidine nucleoside phosphorylase in brain tumors and antitumor effect of 5'-DFUR]
Sarcoma, Kaposi
Morphological and cytogenetic studies of angiosarcoma in Stewart-Treves syndrome.
Thymidine phosphorylase expression in Kaposi sarcoma.
Schistosomiasis
[Expression of vascular growth factors in intestinal tissues in colorectal carcinoma patients with schistosomiasis japonica].
Small Cell Lung Carcinoma
Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer.
Squamous Cell Carcinoma of Head and Neck
Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma.
Effects of smoking and alcohol consumption on 5-fluorouracil-related metabolic enzymes in oral squamous cell carcinoma.
Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma.
Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics.
Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for oral squamous cell carcinoma.
Influence of platelet-derived endothelial cell growth factor/thymidine phosphorylase on the cell cycle in head and neck squamous cell carcinoma in vitro.
The effect of neoadjuvant therapy on the 5-fluorouracil metabolic and relative enzymes of oral squamous cell carcinoma.
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Thymidine phosphorylase expression in oral squamous cell carcinoma.
Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma.
[The expressions of TP, MK and CD105 in laryngeal squamous cell carcinoma and their clinical significance]
Stomach Neoplasms
Alpha-fetoprotein-producing gastric cancer: histochemical analysis of cell proliferation, apoptosis, and angiogenesis.
Angiogenesis and lymphangiogenesis of gastric cancer.
Angiogenesis in gastric cancer: importance of the thymidine phosphorylase expression of cancer cells as an angiogenic factor.
Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer.
Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.
Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer.
Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes.
Cancer-Stromal Cell Interaction and Tumor Angiogenesis in Gastric Cancer.
Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts.
Choice of Capecitabine or S1 in Combination with Oxaliplatin based on Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase Expression Status in Patients with Advanced Gastric Cancer.
Clinical impact of thymidine phosphorylase expression in gastric cancer.
Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.
Correlation between expression levels of thymidine phosphorylase (dThdPase) and clinical features in human gastric carcinoma.
Correlation between spontaneous apoptosis and the expression of angiogenic factors in advanced gastric adenocarcinoma.
Effects of 5'-DFUR and OK-432 on cytokines and thymidine phosphorylase in tumor tissue of gastric cancer patients.
Effects of thymidine phosphorylase levels in cancer, background mucosa, and regional lymph nodes on survival of advanced gastric cancer patients receiving postoperative fluoropyrimidine therapy.
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Expression of thymidylate synthase and thymidine phosphorylase in recurrence and survival rates of advanced gastric cancer.
Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
Expressions of Thymidylate Synthase,Thymidine Phosphorylase, Class III ?-tubulin, and Excision Repair Cross-complementing Group 1predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin.
Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil.
H pylori status and angiogenesis factors in human gastric carcinoma.
Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma.
Heterogeneity and clinical role of thymidine phosphorylase activity in gastric cancer.
Immunohistochemical demonstration of angiogenic growth factors and EGF receptor in hepatic metastases and primary human gastric cancer.
Immunohistochemical localization of thymidine phosphorylase in gastric cancer: is there a role of the differential expression in tumor cells and associated stromal cells?
Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Measurement of serum thymidine phosphorylase levels by highly sensitive enzyme-linked immunosorbent assay in gastric cancer.
Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer.
Partial purification of a thymidine phosphorylase from human gastric cancer.
Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.
Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor.
Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers.
Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients.
Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer.
Systemic immune-inflammation index, thymidine phosphorylase and survival of localized gastric cancer patients after curative resection.
The expression of thymidine phosphorylase and its correlation with angiogenesis in gastric adenocarcinoma.
The Expression of Thymidine Phosphorylase in Cancer-infiltrating Inflammatory Cells in Stomach Cancer.
The inhibition of thymidine phosphorylase can reverse acquire 5FU resistance in gastric cancer cells.
The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine.
Thymidine phosphorylase activity and angiogenesis in gastric cancer.
Thymidine phosphorylase activity in tumor correlates with venous invasion.
Thymidine phosphorylase expression correlates with malignant potential and anti-tumor effect of doxifluridine on gastric cancer: multivariate analysis for adjuvant chemotherapy doxifluridine vs. 5-fluorouracil.
Thymidine phosphorylase expression in gastric cancer in association with proliferative activity and angiogenesis.
Thymidine phosphorylase expression is useful in selecting adjuvant chemotherapy for stage III gastric cancer.
Thymidine Phosphorylase/?-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Thymidine phosphorylase/platelet-derived endothelial cell growth factor is upregulated in advanced solid types of gastric cancer.
Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.
[Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase) and clinicopathological factors in patients with gastric cancer]
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase)/platelet-derived endothelial cell growth factor and histological prognostic factor, and influences of 5'-deoxy-5-fluorouridine (5'-DFUR) administration on PyNPase levels. 5'-DFUR Joint Research Group in the Osaka Area for Gastric Cancer]
[Correlation between pyrimidine nucleoside phosphorylase (PyNPase)/thymidine phosphorylase/platelet-derived endothelial cell growth factor and histological prognostic factor, and influence of 5'-deoxy-5-fluorouridine (5'-DFUR) administration on PyNPase activities and serum immunosuppressive acidic protein levels. A study group of oral anti-cancer drugs in Seiban/Tajima area]
[Effect of 5'-deoxy-5-fluorouridine (5'-DFUR) on the activity of pyrimidine nucleoside phosphorylase (pyNPase) in normal and tumor tissues of human stomach]
[Malignancy of gastric cancer analyzed by the expression of thymidine phosphorylase]
[Significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced gastric cancers]
[Study of PyNPase activity in patients with gastric cancer--the association with preoperative IAP values]
[Study on pyrimidine nucleoside phosphorylase (PyNPase) activity in resected tissues of patients with gastric cancer]
[The dynamics of the enzymatic activity of DNA metabolism during the treatment of stomach cancer patients]
[The expression of thymidylate synthase and thymidine phosphorylase in the early-stage of gastric cancer]
Stomach Ulcer
Expression of the angiogenic factor thymidine phosphorylase in THP-1 monocytes: induction by autocrine tumor necrosis factor-alpha and inhibition by aspirin.
Synovitis
Synovial inflammation and hyperplasia induced by gliostatin/platelet-derived endothelial cell growth factor in rabbit knees.
Syringoma
Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.
Thrombocytosis
Poor Prognosis Associated with High Levels of Thymidine Phosphorylase and Thrombocytosis in Patients with Renal Cell Carcinoma.
Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma.
Thymidine phosphorylase gene variant, platelet counts and survival in gastrointestinal cancer patients treated by fluoropyrimidines.
Thrombosis
Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.
Increased expression of platelet-derived endothelial cell growth factor in human hepatocellular carcinomas correlated with high Edmondson grades and portal vein tumor thrombosis.
Targeting Thymidine Phosphorylase With Tipiracil Hydrochloride Attenuates Thrombosis Without Increasing Risk of Bleeding in Mice.
Thymidine Phosphorylase Is Increased in COVID-19 Patients in an Acuity-Dependent Manner.
Thymidine phosphorylase participates in platelet signaling and promotes thrombosis.
Thymidine phosphorylase: A potential new target for treating cardiovascular disease.
[Expression rates of three angiogenic factors in hepatocellular carcinoma and their relation with microvessel density and portal vein tumor thrombosis]
thymidine phosphorylase deficiency
Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy.
Assessment of stability, toxicity and immunogenicity of new polymeric nanoreactors for use in enzyme replacement therapy of MNGIE.
Biochemical abnormalities in a patient with thymidine phosphorylase deficiency with fatal outcome.
Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy.
Deoxyuridine accumulation in urine in thymidine phosphorylase deficiency (MNGIE).
Elevated plasma deoxyuridine in patients with thymidine phosphorylase deficiency.
Genetic study of mutants of Escherichia coli K-12 with a thymidine phosphorylase deficiency.
HPLC-UV analysis of thymidine and deoxyuridine in plasma of patients with thymidine phosphorylase deficiency.
Increased blood-brain barrier permeability with thymidine phosphorylase deficiency.
Mitochondrial neurogastrointestinal encephalomyopathy treated with peritoneal dialysis and bone marrow transplantation.
Mitochondrial neurogastrointestinal encephalomyopathy: case report.
Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B.
Mitochondrial syndromes with leukoencephalopathies.
Proceedings: Investigation of the nucleoside metabolism in Rhizobium lupini: obligatory thymidine phosphorylase deficiency.
Regulation by degradation, a cellular defense against deoxyribonucleotide pool imbalances.
Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency.
Spontaneous abdominal esophageal perforation in a patient with mitochondrial neurogastrointestinal encephalomyopathy.
Thymidine kinase 2 enzyme kinetics elucidate the mechanism of thymidine-induced mitochondrial DNA depletion.
Thymidine phosphorylase deficiency causes MNGIE: an autosomal recessive mitochondrial disorder.
[Fatal cachexia caused by mitochondrial neuro-gastro-intestinal encephalomyopathy].
Thyroid Cancer, Papillary
Increased expression of mRNA specific for thymidine kinase, deoxycytidine kinase or thymidine phosphorylase in human papillary thyroid carcinoma.
Thyroid Neoplasms
Platelet-derived endothelial cell growth factor.
Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture.
Tumor vascularity predicts recurrence in differentiated thyroid carcinoma.
Urinary Bladder Neoplasms
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human bladder cancer.
Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers.
Expression of the fluoropyrimidine-metabolizing enzymes in bladder cancers as measured by the Danenberg tumor profile.
Expression of thymidine phosphorylase in human superficial bladder cancer.
Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer.
IFN gamma-induced up-regulation of PD-ECGF/TP enhances the cytotoxicity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in bladder cancer cells.
Molecular basis for the involvement of thymidine phosphorylase in cancer invasion.
Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.
Novel prophylactic effect of doxifluridine in superficial bladder cancer.
Prognostic significance of platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in stage pT1 G3 bladder cancer.
Prognostic Significance of Thymidine Phosphorylase in Superficial Bladder Carcinoma.
Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.
Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion.
The expression of platelet-derived endothelial cell growth factor in human bladder cancer.
The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.
The role of peroxisome proliferator-activated receptor gamma in bladder cancer in relation to angiogenesis and progression.
Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer.
Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer.
Tissue levels of pyrimidine nucleoside phosphorylase activity in human and rodent bladder cancer and normal bladder tissue.
[Enhancement effect of interferon gamma on the sensitivity of RT4 bladder cancer cells to 5'-deoxy-5-fluorouridine,and 5-fluorouracil through up-regulation of PD-ECGF/TP]
[The analysis of thymidine phosphorylase examined by ELISA in bladder cancer]
[The significance of platelet-derived endothelial cell growth factor mRNA expression in superficial bladder cancer]
Urologic Diseases
Expression of platelet-derived endothelial cell growth factor and its potential role in up-regulation of angiogenesis in scarred kidneys secondary to urinary tract diseases.
Uterine Cervical Neoplasms
Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer.
Clinical implication of expression of platelet-derived endothelial cell growth factor (PD-ECGF) in metastatic lesions of uterine cervical cancers.
Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers.
Different angiogenic pathways in human cervical cancers.
Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers.
Expression of thymidine phosphorylase in human cervical cancer.
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.
Platelet-derived endothelial cell growth factor in keratinizing-type squamous cell uterine cervical cancer.
Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer.
Plausible linkage of hypoxia inducible factor-1alpha in uterine cervical cancer.
Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy.
Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers.
Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis.
Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis.
Uterine Neoplasms
Thymidine phosphorylase expression in tumor stroma of uterine cervical carcinomas: histological features and microvessel density.
Virus Diseases
The next ten stories on antiviral drug discovery (part E): Advents, Advances, and Adventures.
Vulvar Diseases
Angiogenesis in benign, pre-malignant and malignant vulvar lesions.
Vulvar Neoplasms
Role of angiogenesis in benign, premalignant and malignant vulvar lesions.